



(51) International Patent Classification:

A61K 31/435 (2006.01) A61K 31/4375 (2006.01)

(21) International Application Number:

PCT/US2012/062850

(22) International Filing Date:

31 October 2012 (31.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/553,854 31 October 2011 (31.10.2011) US

(71) Applicant: THE METHODIST HOSPITAL RE-SEARCH INSTITUTE [US/US]; 6565 Fannin, MS D-200, Houston, TX 77030 (US).

(72) Inventors; and

(71) Applicants : BASKIN, David, S. [US/US]; 1656 North Boulevard, Houston, TX 77006 (US). SHARPE, Martyn, Alun [GB/US]; 1908 Marshall Street, Apt. #2, Houston, TX 77098 (US).

(74) Agents: MOORE, Mark, D. et al.; Haynes and Boone, LLP, 2323 Victory Avenue, Suite 700, Dallas, TX 75219 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUND COMPRISING A MAO TARGETING/ SEEKER MOIETY FOR TREATING HUMAN GLIOMAS




FIG. 27

(57) Abstract: Disclosed are compound for targeting chemotherapeutic agents to mammalian mitochondria. Also disclosed are monoamine oxidase compositions, and methods of using them for the selective therapy of mammalian cancers, and in particular, in the treatment of human gliomas. Also disclosed are methods employing the novel targeted chemotherapeutics with one or more conventional anti-cancer therapies, including, for example, radiotherapy.

DESCRIPTION

COMPOUND COMPRISING A MAO TARGETING/ SEEKER MOIETY FOR TREATING HUMAN GLIOMAS

BACKGROUND OF THE INVENTION

5 The present application claims priority to United States Provisional Patent Application 61/553,854, filed October 31, 2011, the entire contents of which is specifically incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

10 The present invention generally relates to pharmaceutical compositions and oncological treatment methods. In particular, the invention provides improved compositions for targeting chemotherapeutics to mitochondria, and methods for selective therapy of mammalian cancers, and in particular, human cancers such as gliomas.

15 DESCRIPTION OF RELATED ART

GLIOMAS: PROGNOSIS AND TREATMENT

Nearly 10,000 Americans each year are diagnosed with malignant glioma. Of those, 50% survive one year, and only 20% survive two years. Five-year survival rate is <3%. Conventional treatment consists of a triad: surgery (if the location allows it),
20 radiotherapy, and chemotherapy. After surgery, chemotherapy (normally in the form of DNA acylating agents such as temozolomide or carmustine or more rarely, the topoisomerase inhibitor, irinotecan) is initiated. In certain patients, carmustine may also be delivered in the form of wafers placed into the post-surgical wound.

Gliomas are the most common malignant brain tumors reported in humans.
25 Gliomas are neuronal malignancies that arise from an uncontrolled proliferating cell of the central nervous system. Patients diagnosed with gliomal cancer have a dismal prognosis, and although symptoms vary with the particular site of the tumor, they tend to develop very quickly due to the rapid growth behavior of the tumor cell. Gliomas can originate from several cell types including ependymal cells, astrocytes, oligodendrocytes and
30 different types of glia cells. Clinically, gliomas are divided into four grades, which are determined by pathologic evaluation of the tumor. Low-grade gliomas are well-differentiated and slower growing, thus biologically less aggressive, and therefore offer a relatively better prognosis for the patient. Conversely, high-grade gliomas are anaplastic, fast-growing, and invasive towards adjacent tissues. Consequently, high-grade gliomas

offer a worse prognosis for the patient. . Unfortunately, the most aggressive of these grades, grade 4 or glioblastoma multiforme (GBM), is also the most frequent in humans. Because most patients with GBMs die of their disease in less than a year (and essentially *no* GBM patient has what would be considered a “long-term survival”), the development of more effective treatment regimens for the disease has been vigorously pursued for more than fifty years, with, unfortunately, only limited success to date.

CANCERS, MITOCHONDRIA AND HYDROGEN PEROXIDE AS A MITOGEN

Hydrogen peroxide is a product of mitochondrial respiration, which produces superoxide by the one-electron reduction of molecular oxygen with hydrogen; peroxide is then generated by the action of superoxide dismutase or due to spontaneous dismutation (Vizi, 2000; Boveris and Chance, 1973). Hydrogen peroxide is a potent mitogen, particularly in microglia (Jekabsone *et al.*, 2006; Mander *et al.*, 2006). Cancer cells produce high amounts of hydrogen peroxide, which is linked to key alterations in cancer, including cell proliferation, apoptosis resistance, metastasis, angiogenesis and hypoxia-inducible factor 1 activation (Droge, 2002). In the absence of mitochondrially-generated hydrogen peroxide, many cancers upregulate other enzymes, which produce hydrogen peroxide as a byproduct of their function. One such enzyme is monoamine oxidase.

MONOAMINE OXIDASE B IN GLIOMA

Monoamine oxidase B (MAO-B) catalyzes deamination of dopamine through a two-electron reduction of oxygen to hydrogen peroxide. In the brains of primates and mice, it is found only in the glia and dopaminergic neurons. The activity of MAO-B is four-fold greater in glioblastoma multiforme, low-grade astrocytomas and in anaplastic astrocytomas than in postmortem control brains or meningiomas (Gabilondo *et al.*, 2008). It appears that hydrogen peroxide is generated by gliomal MAO-B is part of a proliferation signal. Interestingly, in high grade prostate cancer there is a four fold increase in MAO-A and again the mitotic hydrogen peroxide signaling resulting from up-regulation may be the trigger for this increase in lethality (Flamand *et al.*, 2010).

EXOGENOUS MAO-B-SPECIFIC SUBSTRATES

The best-known exogenous substrate of MAO-B is (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (MPTP), which is converted to its cationic form, 1-methyl-4-phenylpyridinium (MPP⁺), by glial cells. MPP⁺ is a dopamine mimetic, and is

concentrated inside dopaminergic neurons *via* the dopamine transporter. Inside these neurons, MPP⁺ undergoes a second concentrating effect; moving into their mitochondria in response to the membrane potential, $\Delta\Psi$, causing both inhibition and superoxide generation at Complex I, which can result in loss of mitochondrial function, caspase
5 activation, dopaminergic cell apoptosis, and phenotypically, Parkinson's disease (Fukuda, 2001).

DEFICIENCIES IN THE PRIOR ART

One of the reasons for the resistance of GBM to therapeutic treatments is the
10 complex character of the tumor itself. As the name GBM implies, glioblastoma is multiforme. It is multiforme both grossly (often presenting regions of necrosis and hemorrhage) and microscopically (complete with regions of pseudopalisading necrosis, pleomorphic nuclei and cells, and microvascular proliferation). Moreover, GBM is genetically diverse, with various deletions, amplifications, and point mutations leading to
15 activation of signal transduction pathways downstream of tyrosine kinase receptors such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), as well as to disruption of cell-cycle arrest pathways by INK4a-ARF loss or by p53 mutations associated with cyclin-dependent kinase 4 (CDK4) amplification or retinoblastoma-protein (Rb) loss.

20 Compounding the difficulty in successful GBM treatment is the fact that surgical resection of the tumor is hampered by the topographically-diffuse nature of the tumors themselves. Moreover, the location of the GBM tumor cells within the brain can also be highly variable, resulting in the inability to completely resect this tumor. Glioma cells migrate away from the initial tumor through the brain parenchyma, collect just below the
25 pial margin (subpial spread), surround neurons and vessels (*e.g.*, perineuronal and perivascular satellitosis), and migrate through the white matter tracks (*e.g.*, intrafascicular spread). As a result, the individual tumor cells diffuse over long distances, and into areas of the brain that are essential for the patient's survival. An extreme example of this behavior is a condition referred to as "gliomatosis cerebri," in which the entire brain is
30 diffusely infiltrated by neoplastic cells with minimal or no central focal area of tumor *per se*. Although gliomas do not metastasize *via* the bloodstream, they can spread *via* cerebrospinal fluid and cause what is referred to as "drop metastases" in the spinal cord. Fully one quarter of patients with GBM demonstrate multiple or multi centric GBMs at autopsy. Consequently, the infiltrative growth pattern of these tumors precludes curative

neurosurgery, and high-grade gliomas almost always recur even after what was thought to be “complete” surgical resection.

Despite recent advances in therapy, treatment of malignant gliomas remains palliative. Median post-diagnosis survival for anaplastic astrocytoma is less than 3 years and for glioblastoma multiforme is typically only 12 to 14 months. Temozolomide, an oral methylating chemotherapeutic agent, became standard of care for newly diagnosed glioblastoma when used concurrently with external beam radiation followed by adjuvant therapy, although GBM continue to be highly resistant to radiation. Under even the best of circumstances (in which essentially all of the tumor can be surgically removed and the patients are fully treated with radiation and chemotherapy), the mean survival of this disease is extended only by a period of a few months.

The poor outcome of the standard treatments for GBM coupled with the diffuse nature of the disease itself, have influenced a number of attempts at novel therapeutic approaches with the aim of also killing neoplastic cells disseminated from the main tumor. To date, however, the only significant therapeutic options for GBM are limited to surgery, radiotherapy and conventional chemotherapy using drugs such as carmustine, lomustine, vincristine, procarbazine, carboplatin, *cis*-platin, etoposide, irinotecan, and its active metabolites, and related agents.

Concurrent administration of temozolomide (TMZ) and radiotherapy (RT) has emerged as the primary ‘standard of care’ for patients with newly diagnosed GBM. A clinically-meaningful improvement in survival compared to RT alone has been demonstrated, but the increase is still disappointing (median survival time for patients treated with TMZ/RT is 15 months, *vs.* only 12 months for patients treated with RT alone).

In spite of the successful introduction of TMZ-based combination therapy, however, clinicians still concur that there remains a significant need for the development of new chemotherapeutically-active agents for use in the treatment of glioma, and particularly for GBM and advanced stages of the disease. Similarly, there remains a significant, unmet need in the medical arts for new chemotherapeutic agents effective in the prevention, treatment, and/or amelioration of one or more symptoms of hyperproliferative disorders, and particularly for aggressive forms of mammalian cancers, such as human gliomal tumors.

Primary brain tumors are classified into more than 10 types according to their origin of onset and pathological tissue type, examples of which include glioma and meningioma. Gliomas are particularly serious in terms of both incidence and malignancy,

and are classified into seven or more types such as glioblastoma and anaplastic astrocytoma according to their detailed pathological tissue type. Disease stage (*i.e.*, tumor size, presence of distal metastasis) and histological malignancy are used to determine the degree of malignancy of primary brain tumors, with histological malignancy being classified into four levels of advancing degree of malignancy (G1 to G4). For example, the malignancy of glioblastoma is G4 (WHO4), while the malignancy of anaplastic astrocytoma is G3 (WHO3), and both G3 and G4 are classified as malignant. Thus, those primary brain tumors that should first be targeted by anti-brain tumor agents are gliomas, and particularly glioblastoma or anaplastic astrocytoma associated with a high degree of malignancy.

Although definitive efficacy of chemotherapy has only been confirmed for alkylating agents and temozolomide, their efficacy is limited to concomitant use with radiotherapy. Post-surgical radiotherapy has also been demonstrated to demonstrate life-prolonging (albeit brief) effects.

Therefore, an important object of the present invention is to provide novel compounds (and pharmaceutical that include them) for use in chemotherapeutic methods aimed at treating malignant cancer in affected animals, and in particular, in mammals such as humans, diagnosed with one or more forms of glioma.

BRIEF SUMMARY OF THE INVENTION

The present invention addresses these and other unmet deficiencies inherent in the relevant oncological and pharmaceutical arts, by providing novel, non-obvious, and useful tripartite compounds (as well as compositions comprising them) for preventing, treating, and/or ameliorating one or more symptoms of at least a first mammalian cancer. In an overall and general sense, these compounds preferably include at least a first targeting or “seeker” moiety that is operably linked (preferably *via* at least a first chemical linker molecule), to at least a first therapeutic moiety. Preferably, the first therapeutic moiety is a neutral, blood brain barrier permeable molecule, and in particular embodiments, is an inactive, or substantially inactive, pro-drug. Such therapeutic moieties are preferably DNA acylating or DNA damaging agents, and in certain embodiments, is a “nitrogen mustard,” a “sulfur mustard,” a platin tetranitrate, vinblastine, docetaxel, etoposide, camptothecin (or one of its active metabolites such as SN38, lomustine, carmustine, or a derivative, an analog, a salt or any combination thereof.

In particular, the present invention overcomes various limitations inherent in the prior art by providing novel compositions and methods for treating human gliomas. In illustrative embodiments, the inventors have synthesized and tested pro-drug compounds, which are MAO-B-specific substrates that have been specifically designed to kill cancer cells such as human gliomas. After oxidation of the pro-drug, the cationic mature drug preferentially accumulates in the mitochondria of the targeted cancer cells, where it acylates mitochondrial DNA and ribosomal RNA, and thereby inactivates and/or kills the cancer cells by disrupting the normal function of the mitochondria.

Using an enzyme that is highly “up-regulated” in glioma, MAO-B, neutral, blood-brain-barrier permeable pro-drugs, including, for example MP-MUS and SN38, have been prepared and shown to be highly active against cancer cells via the MAO-B conversion into impermeable active species, P⁺-MUS, and APE-SN38, respectively. By ensuring that the mature drug is a cationic species that targets mitochondria, a linked chemotherapeutic, such as the DNA acylating agent, nitrogen mustard can be selectively delivered in concentrations effective to destroy the mitochondrial DNA. While MOA-B is found in normal glia, the enzyme is up-regulated at least five-fold in gliomas, making it an ideal candidate for selectively targeting chemotherapeutic agents to gliomal mitochondria, since mitochondria are required by gliomal cells for pyrimidine synthesis. In addition, because mitochondrial DNA damage does not increase the typical base-excision repair pathways that are typically associated with nuclear DNA damaging chemotherapeutic resistance, the delivery of the chemotherapeutic preferentially to the mitochondria offer significant advantages over conventional chemotherapeutic protocols.


The present invention provides new and useful compounds that may advantageously be used to selectively target one or more chemotherapeutic agents to mammalian mitochondria. The invention also provides novel compositions comprising these compounds, as well as methods of use for these compounds, including, for example, in the preparation of medicaments for the therapeutic treatment of one or more mammalian hyperproliferative disorders, including, for example, human gliomal cancers and the like.

To exploit the chemotherapeutic action of cytotoxic compounds useful in chemotherapy regimens, the inventors have developed unique targeting moieties whose activity is modulated by the activity of an enzyme that is up-regulated in many types of cancer cells, including GBM. These novel targeting moieties permit the delivery of a non-cytotoxic pro-drug to cells, which is then transformed into a cytotoxic, active chemotherapeutic agent *via* accumulation within the mitochondria of mammalian cells,


where the compounds exert their cytotoxic effect(s), including for example, DNA acylation and damage. The targeted delivery of such cytotoxic active compounds, by designing them to be preferentially uptaken by cellular mitochondria across the mitochondrial membrane, improve the efficacy of the delivered chemotherapeutic, while at the same time, lowering the amount of cytotoxic agent to other compartments of the cell, including, for example, the nucleus.

Preferably, the compounds disclosed herein are multi-component in nature, such that each compound preferably includes one or more “targeting” or “seeker” moieties operably linked (either directly or indirectly, by the incorporation of one or more chemical linkers) to one or more “cytotoxic” or “chemotherapeutic” moieties, wherein the initial pro-drug form of the compound is substantially “inactive” (*i.e.*, non-cytotoxic), but whereupon is converted to an “active” (*i.e.*, a cytotoxic or chemotherapeutic “warhead”) form by the enzymatic catalysis of the pro-drug to the active drug by a mammalian enzyme such as monoamine oxidase (MAO), and in particular, by the enzymatic action of MAO-B. In particularly preferred embodiments, the pro-drug is preferentially converted to active drug by the enzymatic action of MAO-B, but remains substantially un-converted to active drug by the action of the related enzyme, MAO-A. In certain embodiments, the specificity of the multicomponent compound for MAO-B is at least about 10 times greater, more preferably, at least about 15 times greater, and more preferably still, about 20 times greater or more than for MAO-A. In illustrative embodiments, the inventors have designed multicomponent compounds that are at least about 10-fold more specific for MAO-B catalysis than for catalysis by MAO-A.


An exemplary substrate of MAO-B that is useful in the development of the tripartite compounds of the present invention is MPTP. MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, is shown in general formula 1:



MPTP can be converted by MAO-B to MPP⁺ (1-methyl-4-phenylpyridinium), shown in general formula 2:



An exemplary chemotherapeutic compound that was employed in the development of the tripartite compounds of the present invention, MPTP was chemically linked to a nitrogen mustard, to form MP-MUS (I), (N,N-bis(2-chloroethyl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl) propanamide) (general formula 3). MP-MUS is composed of a mitochondrial targeting, or “seeker” moiety, MP, operably linked to a cytotoxic moiety, nitrogen mustard, via a chemical linker. MP-MUS (3) has been shown to be



(3)

effective in primary glioma cell cultures. In these studies, MP-MUS (I) killed gliomal cells at chemotherapeutic dosages; collapsed the mitochondrial membrane potential, increased mitochondrial protein levels and caused large numbers of mtDNA breaks. The effects of the pro-drug were almost completely negated by the addition of the MAO-B specific inhibitor, selegiline.

In illustrative embodiments, the chemotherapeutic moiety is operably linked to the targeting/seeker moiety by at least one linker group, such as 2-methylpropanamide and cyclohexane, to provide a therapeutic/linker combination including one or more selected from the group consisting of bis(2-chloroethyl) [Linker-TP]amine, 1-[(2-R1-2-R2-2-[Linker-TP]ethyl)sulfanyl]-3-chloropropane, ({[(3-chloropropyl)sulfanyl]methyl})[Linker-TP]-R1-amine, 3-[Linker-TP]-4-(methanesulfonylmethoxy)butyl methanesulfonate, 1,10-dichloro-5-[Linker-TP]-2,9-diaza-1,10-diplatinadecane-1,1,10,10-tetramine, and 2,2-diamino-5-[Linker-TP]-1,3-dioxo-2-platinacyclohexane-4,6-dione.


Preferably, the first targeting/seeker moiety is specifically recognized as a substrate for a mammalian monoamine oxidase (MAO) enzyme, including for example MAO-A and MAO-B forms of the enzyme. In the practice of the invention, the targeting/seeker molecule confers selectivity to the compound, such that it confers to the compound at least two-fold (and preferably at least three-fold more, or even four-fold more or greater) greater specificity for one form of the MAO enzyme (preferably MAO-B), than for another form of the enzyme (e.g., MAO-A).

Through the action of MAO, the targeting/seeker moiety is converted to its corresponding 1-methyl-4-(X)-pyridinium cationic form, wherein the resulting 1-methyl-4-


(X)-pyridinium cationic form of the targeting moiety facilitates an enhanced uptake of the compound across the mitochondrial membrane of a mammalian cell at a rate that is at least 10-fold (and preferably at least 15-fold, at least 20-fold, or at least 30-fold) higher than that of the corresponding non-ionic form of the targeting moiety. This increased ability of the targeting/seeker moiety to translocate the compound across the mitochondrial membrane (due substantially in part to the high electrical potential across that membrane) such that the presence of the 1-methyl-4-(X)-pyridinium cation facilitates accumulation of the compound in the mitochondria of a population of mammalian cells to which the compound has been administered, in an amount that is about 50-fold (any more preferably, at least about 100-fold, at least about 200-fold, or even about 500-fold) higher than the concentration of the compound that remains in the cytosolic fraction of such cells.

In exemplary embodiments, the targeting/seeker moiety is selected from the group consisting of 1-methyl-1,2,3,6-tetrahydropyridine and 1-cyclopropyl-1,2,3,6-tetrahydropyridin-.

Exemplary compounds in accordance with the present invention include, without limitation, 2-R₃-N-R₂-N-R₁-2-(1-X-1,2,3,6-tetrahydropyridin-4-yl) acetamide, 4-phenyl-1-X-1,2,3,6-tetrahydropyridine, 4-cyclohexyl-1-X-1,2,3,6-tetrahydropyridine, and 4-(5-R₁-4-R₂-3-R₃-furan-2-yl)-1-X-1,2,3,6-tetrahydropyridine, wherein R₁, R₂, R₃, and R₅, are each halogen, hydroxyl, oxo, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkoxy, alkylthio, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, -NR_aR_b, -NR_aC(=O)R_b, -NR_aC(=O)NR_aNR_b, -NR_aC(=O)OR_b, -NR_aSO₂R_b, -C(=O)R_a, C(=O)OR_a, -C(=O)NR_aR_b, -C(=O)NR_aR_b, -OR_a, -SR_a, -SOR_a, -S(=O)₂R_a, -OS(=O)₂R_a, -S(=O)₂OR_a, substituted alkyl, substituted aryl, substituted arylalkyl, substituted heterocycle, or substituted heterocyclealkyl; wherein R_a and R_b are the same or different and, are, independently, hydrogen, alkyl, haloalkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl, and further wherein X is a therapeutic moiety. In preferred embodiments, X is a chemotherapeutic drug selected from the group consisting of a nitrogen mustard, a sulfur mustard, a platinum tetranitrate, *cis*-platin, or a derivative or salt thereof. In illustrative embodiments, the compound is MP-MUS or



a functionalized form of the camptothecin active metabolite, SN38:



In another aspect of the invention, a pharmaceutical composition is provided that includes one or more of the compound disclosed herein, admixed with one or more pharmaceutically-acceptable carriers, diluents, excipients, or any combination thereof, as described elsewhere herein.. In some embodiments, the composition may further optionally include one or more other antineoplastic, cytotoxic, cytostatic, or chemotherapeutic agents, or any combination thereof. Exemplary agents include, without limitation, sulfans, platin tetranitrates, nitrogen mustards, sulfur mustards, *cis*-platin, topoisomerase inhibitors (including topoisomerase I and II inhibitors), as well as derivatives, analogs, salts, active metabolites, or combinations thereof.

In an exemplary embodiment, the one or more other antineoplastic agents is selected from the group consisting of camptothecin, irinotecan, temozolomide, vinblastine, docetaxel, etoposide, carmustine, lomustine, a nitrogen mustard, a sulfur mustard, an active metabolite of camptothecin (such as SN38), and any combination thereof.

The invention also provides a method of treating or ameliorating one or more symptoms of cancer in an animal in need thereof. Such a method generally includes at least the step of providing or administering to the animal, either systemically, or locally at one or more regions or sites within, or about the body of the animal an effective amount of at least a first chemotherapeutic compound disclosed herein, or an analog, an agonist, an antagonist, or a derivative or salt thereof, for a time sufficient to treat or ameliorate the one or more symptoms of the cancer in the animal.

In a further aspect, the invention also provides a method for inhibiting the growth of a cancer cell or tumor in an animal. This method, in an overall and general sense includes providing to one or more cells or tissues of the body of an animal in need thereof, an amount of one or more of the chemotherapeutic compound disclosed herein, or an analog, an agonist, an antagonist, or a derivative or salt thereof, in an amount and for a time effective to inhibit the growth of the cancer cell or the tumor.

In another aspect, the invention provides a method for treating cancer in a subject, and preferably in a human. In an overall and general sense, the method generally includes administering to the subject in need thereof a therapeutically-effective amount of one or more of the chemotherapeutic compounds disclosed herein, or an analog, an agonist, an antagonist, or a derivative or salt thereof; and administering one or more additional chemotherapeutics, or a therapeutically effective amount of an ionizing radiation, or combinations thereof.

The invention also provides a method of ameliorating one or more symptoms of cancer in an animal. Such methods generally include providing to the animal an effective amount of a chemotherapeutic composition that comprises one or more of the therapeutic compounds disclosed herein, or an analog, an agonist, an antagonist, or a derivative or salt thereof, and at least a first pharmaceutically-acceptable diluent, for a time sufficient to ameliorate the one or more symptoms of the cancer in the animal.

A further method is provided by the invention for altering, affecting, increasing, or improving the effectiveness of a chemotherapeutic agent in damaging or killing one or more types of cancer cells or tumors in an animal. This method generally involves chemically linking such an agent to a MAO-convertible, mitochondria-targeting/seeking drug delivery moiety to form a mitochondrially-targeted composition, and then providing an effective amount of the resulting chemotherapeutic composition to one or more cells, tissues, or organs of the animal, wherein the effectiveness of the composition for killing one or more cancer cells in the animal is greater than the effectiveness of the un-linked agent alone.

The invention also provides a method of targeting a chemotherapeutic agent to one or more cancer cell mitochondria in an animal in need of anti-cancer therapy. Such a method generally includes the process of chemically linking one or more mitochondrially-active, chemotherapeutic agents to one or more inactive pro-drugs that, when present in the mitochondria exhibit at least a first chemotherapeutic property (e.g., DNA damaging or acylating activity). Such a compound is preferably convertible from its inactive pro-drug

form to an active form by the enzymatic action of a mitochondrial MAO into the corresponding cationic form, which is then able to cross the mitochondrial membrane at a relatively high degree of efficiency, and in an amount that has resulting cytotoxic properties, and then providing an effective amount of the composition to one or more cells, tissues, or organs of the animal, wherein the level of chemotherapeutic agent localized to the mitochondria is substantially higher than the level of chemotherapeutic agent remaining in the cytosol of the one or more cancer cells. Such exemplary compounds include, without limitation, MP-MUS or APE-SN38.

In the practice of the present methods, the hyperproliferative condition is preferably one or more cancers, including without limitation, gliomal cancers, such as Glioblastoma Multiforme (GBM), recurrent Glioblastoma Multiforme (rGBM), astrocytoma, ependymoma, oligodendroglioma, brainstem glioma, or mixed glioma. Such cancers may be diagnosed as, or identified as, an advanced-stage or an advanced-grade type of cancer, including, without limitation, advanced-stage GBM. Such malignant gliomas may include one or more types of radiation-resistant glioma, or glioma stem cells.

Exemplary additional agents, which may be co-administered to the subject, include, without limitation, one or more conventional anti-cancer drugs, such as camptothecin, temozolomide, carmustine, and combinations thereof. Alternatively, the methods of the present invention may also include one or more surgical interventions, such as tumor resection, or may further optionally include one or more courses of therapeutically effective ionizing radiation (*i.e.*, radiation therapy).

The invention also provides pharmaceutical composition for use in the therapy of cancer in an animal subject, wherein the composition comprises one or more of the chemotherapeutic compounds disclosed herein, and may include such a use for preventing, treating, or ameliorating one or more symptoms of malignant glioma in a human subject.

In another aspect, the invention provides a MAO-convertible (and in particular, a MAO-B-convertible) tetrahydropyridine chemotherapeutic targeting/seeking moiety operably linked to at least a first chemotherapeutic agent. Such an agent may include, without limitation, a nitrogen mustard, a sulfur mustard, a sulfan, *cis*-platin, a platin tetranitrate derivative, temozolomide, camptothecin, carmustine, lomustine, or any derivative or analog thereof. Preferably, the MAO-B convertible tetrahydropyridine chemotherapeutic targeted delivery compound has the general formula 1-methyl-4-(X)-pyridine, wherein X is as defined as in FIG. 23. In exemplary embodiments, the MAO-B

convertible tetrahydropyridine chemotherapeutic delivery compound is defined as MP-MUS or APE-SN38.

In the practice of the invention, “seeker/linker/warhead” tripartite compounds of the present invention are preferably combined with one or more pharmaceutically-acceptable vehicles or carriers to provide therapeutic medicament compositions that find particular utility in the treatment and/or amelioration of at least a first symptom of one or more mammalian (and in particular, human) diseases, dysfunctions, disorders, abnormal conditions, and the like. In a particularly preferred embodiment, these MAO-converting pro-drug compounds may be provided in pharmaceutical compositions, suitable for delivery to an animal for use in the diagnosis, treatment, prevention, and/or ameliorating at least one or more symptoms of at least a first hyperproliferative-related disorder in an animal, and preferably a disorder including mammalian cancers, such as human glioma, and the like.

The invention also provides a method of altering, affecting, destroying, or killing one or more mammalian cells within or about the body of an animal that has, is suspected of having, or has been diagnosed with one or more forms of mammalian cancer. Such methods generally involve providing to one or more animal cells a therapeutically-effective amount of one or more of the disclosed chemotherapeutic formulations for a time sufficient to treat, and/or ameliorate the one of more symptoms of such a disease.

Also provided herein are methods of altering, modulating, controlling, increasing, and/or attenuating at least one component, pathway, enzyme, or step involved in the process of hyperproliferative cell growth within or about the body of an animal, by providing to one or more cells, tissues, and/or organs of a subject in need thereof an effective amount of one of more of the disclosed therapeutic compositions for a time effective to alter, modulate, control, increase, and/or attenuate at least one component, pathway, enzyme, or step involved in the process of hyperproliferative cell growth within such cells, tissues, organ, and/or body.

Further provided herein are methods of treating, preventing, and/or ameliorating at least one symptom of a mammalian cancer, including, without limitation, human gliomas.

Further provided herein are methods and pharmaceutical formulations for controlling the rate, extent, and/or metabolism of at least a first mammalian cell, in one or more cancers, solid tumors, and the like. In certain embodiments, the method generally includes administration to such cells and/or tissues a first chemotherapeutic compound in accordance with the present invention, in an amount and for a time effective to disrupt,

damage, alter, or impair synthesis of one or more mitochondrial nucleotides (for example, by inducing DNA damage through one or more DNA-acylating “warhead” moieties as described herein), to facilitate sufficient damage to the function of such mitochondria (and the cells in which they are located) to disrupt or kill one or more such cells (and preferably, part or all of a mammalian tumor containing such cells) within or about the body of an animal, in an amount and for a time sufficient to facilitate killing of the cancer, and/or destruction of the cancerous tumor within the body of a patient receiving such therapy.

Also provided herein are methods of treating, preventing, and/or ameliorating at least one symptom of a human hyperproliferative disorder (such as a mammalian glioma and the like) within one or more (and preferably within a plurality) of cancerous cells, tissues, tumors, and the like in an animal undergoing therapy and/or cancer treatment. In certain embodiments, the disclosed multifunctional compounds will be designed such that an inactive pro-drug form of the compound may be delivered to the animal, and then, through the intracellular action of the enzyme MAO, facilitate conversion of the pro-drug, to an active chemotherapeutic metabolite that is effective to control, prevent, or facilitate destruction of one or more cancerous cells populations within the body of the patient undergoing treatment. In such embodiments, the method generally involves administration of at least a first MAO-activatable compound to the animal in an amount and time sufficient to alter the expression or modulate the activity of one or more hyperproliferative, cancerous cells. While the methods are likely to provide benefit for a variety of oncologically-related conditions, the concentration of such activated “warhead” chemotherapeutic agents in the mitochondria of cancer cells, this mitochondrial membrane potential-facilitating accumulation in the cancer cells, necessarily provides advantageous properties compared to conventional chemotherapeutic agents, in that it facilitates lower whole-body doses of the agent to the animal, and preferential facilitates activation of the chemotherapeutic agent by the activity of mitochondrial MAO enzymes in cancerous cells and/or tumorigenic tissues. Such is particularly contemplated to be desirable when localized destruction or inactivation of particular cancer cell/tumor populations within the body of an animal is sought.

In related aspects, the compounds and compositions of the present invention may be utilized to diminish the activity of, or bring about the destruction of particular types of cells within the body of an animal receiving such compositions, either in a targeted (*i.e.*, localized), or a generalized (*i.e.*, systemic) administration. In such embodiments, the method generally involves administration of at least a first inactive pro-drug compound in

an amount and time sufficient to diminish or inhibit the activity of one or more types of tumor cells within the body of an animal selected to receive the treatment., wherein the action of one or more cellular monoamine oxidases results in the conversion of the inactive pro-drug into an active chemotherapeutic metabolite that is preferentially active in the mitochondria of such cells.

Accordingly, in light of the present teachings, pharmaceutical compositions can now be designed that comprise a “seeker” moiety linked to a “warhead” (directly, or by one or more chemical linkers) that are MAO-activatable.

10 CHEMOTHERAPEUTIC COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF

The compounds of the present invention, as well as composition comprising them may be employed in the practice of the invention as a single cancer treatment modality, or alternatively may be combined with one or more additional therapeutic, diagnostic, and/or prophylactic agents, including, without limitation, one or more proteins, peptides, polypeptides (including, without limitation, enzymes, antibodies, antigens, antigen binding fragments *etc.*); RNA molecules (including, without limitation, siRNAs, iRNAs, mRNAs, tRNAs, and catalytic RNAs, such as ribozymes, and the like), DNA molecules (including, without limitation, oligonucleotides, polynucleotides, genes, coding sequences (CDS), introns, exons, plasmids, cosmids, phagemids, baculovirus, vectors [including, without limitation, viral vectors, virions, viral particles and such like]); peptide nucleic acids, detection agents, imaging agents, contrast agents, detectable gas, radionuclides, or such like, and one or more additional chemotherapeutic agents, surgical intervention (*e.g.*, tumor resection), radiotherapy, and the like., or any combination thereof as part of a multifactorial, or multifocal treatment plan for the affected patient.

The compositions disclosed herein may also further optionally include one or more additional active ingredients, including, without limitation, one or more anti-cancer agents, one or more anti-tumorigenic agents, one or more antineoplastic or cytotoxic agents, one or more transcription factors, immunomodulating agents, immunostimulating agents, neuroactive agents, antiinflammatory agents, chemotherapeutic agents, hormones, so called “trophic factors,” cytokines, chemokines, receptor agonists or antagonists, or such like, or any combination thereof.

The chemotherapeutic formulations of the present invention may also further optionally include one or more additional components to aid, facilitate, or improve delivery of the pro-drug and/or active metabolite preferably to the mitochondria of

cancerous cells, including, without limitation, one or more liposomes, particles, lipid complexes, and may further optionally include one or more binding agents, cell surface active agents, surfactants, lipid complexes, niosomes, ethosomes, transferosomes, phospholipids, sphingolipids, sphingosomes, or any combination thereof, and may
5 optionally be provided within a pharmaceutical formulation that includes one or more nanoparticles, microparticles, nanocapsules, microcapsules, nanospheres, microspheres, or any combination thereof.

Preferably, the chemotherapeutic compounds of the present invention, as well as salts, analogs, and/or derivatives thereof will generally be formulated for systemic and/or
10 localized administration to an animal, or to one or more cells or tissues thereof, and in particular, will be formulated for systemic and/or localized administration to a mammal, or to one or more cancerous cells, tumor tissues, or affected organs thereof. In certain embodiments, the compounds and methods disclosed herein will find particular use in the systemic and/or localized administration of one or more antineoplastic agents to one or
15 more cells or tissues of a human being.

Preferably, drug-delivery formulations of the active compounds disclosed herein will be at least substantially stable at a pH from about 4.2 to about 8.2, and more preferably, will be substantially stable at a pH of from about 5 to about 7.5. Preferably, the active ingredient(s) and targeted drugs will be substantially active at physiological
20 conditions of the animal into which they are being administered.

The present invention also provides for the use of one or more of the disclosed pharmaceutical compositions in the manufacture of a medicament for therapy and/or for the amelioration of one or more symptoms of a disease, disorder, dysfunction, or condition, and particularly for use in the manufacture of a medicament for treating, one or more
25 diseases, dysfunctions, or disorders such as gliomal cancers and tumors in a mammal, and, in a human mammal in particular.

The present invention also provides for the use of one or more of the disclosed chemotherapeutics in the manufacture of a medicament for the treatment of cancer, and in particular, human gliomas. In certain embodiments, the invention also provides “seeker”
30 compounds that may be linked to one or more novel or existing chemotherapeutic compositions to facilitate an improvement in the treatment or prognosis of a mammalian cancer, and a human glioma in particular.

CHEMOTHERAPEUTIC METHODS

Another important aspect of the present invention concerns methods for using the disclosed MAO-activatable pro-drug compositions for treating or ameliorating the symptoms of disease, disorder, dysfunction, or deficiency in a mammal having, suspected
5 of having, or at risk for developing such a condition, and in particular for those mammalian diagnosed with one or more gliomal cancers. Such methods generally involve administering to a mammal (and in particular, to a human in need thereof), one or more of the disclosed anticancer compositions, in an amount and for a time sufficient to treat (or, alternatively ameliorate one ore more symptoms of) gliomal cancers in an affected
10 mammal.

In certain embodiments, the therapy described herein may be provided to the animal as a single treatment modality, as a single administration, or alternatively provided to the patient in multiple administrations over a period of from several hours to several days, from several days to several weeks, or even over a period of several weeks to several
15 months or longer, as needed to treat the cancer. In some aspects, it may be desirable to continue the treatment throughout the lifetime of the patient. In other embodiments, it may be desirable to provide the therapy in combination with one or more existing, or conventional, treatment regimens.

CHEMOTHERAPEUTIC KITS

Kits including one or more of the disclosed chemotherapeutic compositions; and instructions for using the kit also represent preferred aspects of the present disclosure. Such kits may further include one or more of the disclosed anti-cancer compounds, either alone, or in combination with one or more additional therapeutic compounds,
25 pharmaceuticals, and such like.

The kits of the invention may be packaged for commercial distribution, and may further optionally include one or more delivery devices adapted to deliver the chemotherapeutic composition(s) to an animal (*e.g.*, syringes, injectables, and the like). Such kits typically include at least one vial, test tube, flask, bottle, syringe or other
30 container, into which the pharmaceutical composition(s) may be placed, and preferably suitably aliquotted. Where a second pharmaceutical is also provided, the kit may also contain a second distinct container into which this second composition may be placed. Alternatively, the plurality of pharmaceutical compositions disclosed herein may be prepared in a single mixture, such as a suspension or solution, and may be packaged in a

single container, such as a vial, flask, syringe, catheter, cannula, bottle, or other suitable single container.

The kits of the present invention may also typically include a retention mechanism adapted to contain or retain the vial(s) or other container(s) in close confinement for commercial sale, such as, *e.g.*, injection or blow-molded plastic containers into which the desired vial(s) or other container(s) may be retained to minimize or prevent breakage, exposure to sunlight, or other undesirable factors, or to permit ready use of the composition(s) included within the kit.

10 PREPARATION OF MEDICAMENTS

Another important aspect of the present invention concerns methods for using the disclosed chemotherapeutic agents, as well as pharmaceutical formulations including one or more of them, in the preparation of one or more medicaments for treating or ameliorating the symptoms of cancer in an animal, such as a vertebrate mammal.

Such use generally involves administration to an animal in need thereof one or more of the disclosed compositions, in an amount and for a time sufficient to prevent, treat, lessen, or cure the disease, disorder, dysfunction, condition, or deficiency in the affected animal, and/or to ameliorate one or more symptoms thereof.

Compositions including one or more of the disclosed pharmaceutical formulations that include at least one MAO-convertible chemotherapeutic composition also form an important part of the present invention. Particularly desirable, are those formulations that in addition to including one or more such chemotherapeutic agents, also further include at least a first pharmaceutically-acceptable excipient, making the compositions desirable for use in cancer therapy of a mammal, and in the treatment of humans, in particular.

Such formulations may optionally further include one or more additional active ingredients, detection reagents, vehicles, additives or adjuvants, radionuclides, gases, or fluorescent labels as may be suitable for administration to an animal. Such routes of administration are known to and may be selected by those of ordinary skill in the art, and include, without limitation, delivery devices including intramuscular, intravenous, intra-arterial, intrathecal, intracavitary, intraventricular, subcutaneous, or direct delivery, administration, and/or injection into an organ, tissue site, or population of cells in the recipient animal.

The invention also provides methods for providing a therapeutic or prophylactic amount of an MAO-activatable compound to at least a first population of cells or to one or

more tissues within the body of a mammal, with the method generally including providing to a mammal in need thereof an effective amount of a anticancer composition as disclosed herein and for a time effective to provide the desired therapy and/or prophylaxis in the selected cells or tissue of the mammal.

5

PHARMACEUTICAL FORMULATIONS

In certain embodiments, the present invention concerns formulation of one or more chemotherapeutic compounds in a pharmaceutically acceptable composition for administration to a cell or an animal, either alone, or in combination with one or more other modalities of diagnosis, prophylaxis and/or therapy. The formulation of pharmaceutically acceptable excipients and carrier solutions is well known to those of ordinary skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens.

In certain circumstances it will be desirable to deliver the chemotherapeutic compositions disclosed herein in suitably-formulated pharmaceutical vehicles by one or more standard delivery devices, including, without limitation, subcutaneously, parenterally, intravenously, intramuscularly, intrathecally, orally, intraperitoneally, transdermally, topically, by oral or nasal inhalation, or by direct injection to one or more cells, tissues, or organs within or about the body of an animal.

The methods of administration may also include those modalities as described in U.S. Patents 5,543,158; 5,641,515, and 5,399,363, each of which is specifically incorporated herein in its entirety by express reference thereto. Solutions of the active compounds as freebase or pharmacologically acceptable salts may be prepared in sterile water, and may be suitably mixed with one or more surfactants, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, oils, or mixtures thereof. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

For administration of an injectable aqueous solution, without limitation, the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, transdermal, subdermal, and/or intraperitoneal administration. In this regard, the compositions of the present invention may be formulated in one or more pharmaceutically acceptable vehicles, including for example sterile aqueous media, buffers, diluents, *etc.* For example, a given dosage of

active ingredient(s) may be dissolved in a particular volume of an isotonic solution (*e.g.*, an isotonic NaCl-based solution), and then injected at the proposed site of administration, or further diluted in a vehicle suitable for intravenous infusion (*see, e.g.*, “Remington’s Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). While some
5 variation in dosage will necessarily occur depending on the condition of the subject being treated, the extent of the treatment, and the site of administration, the person responsible for administration will nevertheless be able to determine the correct dosing regimens appropriate for the individual subject using ordinary knowledge in the medical and pharmaceutical arts.

10 Sterile injectable compositions may be prepared by incorporating the disclosed drug delivery vehicles in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions can be prepared by incorporating the selected sterilized active ingredient(s) into a sterile vehicle that contains the basic dispersion medium and the
15 required other ingredients from those enumerated above. The compositions disclosed herein may also be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein), and which are formed with inorganic acids such as, without limitation, hydrochloric or phosphoric acids, or organic acids such as, without limitation, acetic, oxalic, tartaric,
20 mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, without limitation, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine, and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation, and in such amount as is effective for the intended
25 application. The formulations are readily administered in a variety of dosage forms such as injectable solutions, topical preparations, oral formulations, including sustain-release capsules, hydrogels, colloids, viscous gels, transdermal reagents, intranasal and inhalation formulations, and the like.

30 The amount, dosage regimen, formulation, and administration of the chemotherapeutic compositions disclosed herein will be within the purview of the ordinary-skilled artisan having benefit of the present teaching. It is likely, however, that the administration of a therapeutically-effective (*i.e.*, a pharmaceutically-effective) amount of the disclosed anti-cancer compositions may be achieved by a single administration, such as, without limitation, a single injection of a sufficient quantity of the delivered agent to

provide the desired benefit to the patient undergoing such a procedure. Alternatively, in some circumstances, it may be desirable to provide multiple, or successive administrations of the MAO-modulatory anticancer compositions disclosed herein, either over a relatively short, or even a relatively prolonged period, as may be determined by the medical practitioner overseeing the administration of such compositions to the selected individual.

Typically, formulations of one or more of the active ingredients described herein will contain at least a chemotherapeutically-effective amount of the active agent(s). Preferably, the formulation may contain at least about 0.001% of each active ingredient, preferably at least about 0.01% of the active ingredient, although the percentage of the active ingredient(s) may, of course, be varied, and may conveniently be present in amounts from about 0.01 to about 90 weight % or volume %, or from about 0.1 to about 80 weight % or volume %, or more preferably, from about 0.2 to about 60 weight % or volume %, based upon the total formulation. Naturally, the amount of active compound(s) in each composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological $t_{1/2}$, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one of ordinary skill in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

Administration of the chemotherapeutic compositions disclosed herein may be administered by any effective method, including, without limitation, by parenteral, intravenous, intramuscular, or even intraperitoneal administration as described, for example, in U.S. Patents 5,543,158, 5,641,515 and 5,399,363 (each of which is specifically incorporated herein in its entirety by express reference thereto). Solutions of the active compounds as free-base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose, or other similar fashion. The pharmaceutical forms adapted for injectable administration include sterile aqueous solutions or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions including without limitation those described in U.S. Patent 5,466,468 (which is specifically incorporated herein in its entirety by express reference thereto). In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be at least sufficiently stable under the conditions of manufacture and storage, and must be preserved against the contaminating action of microorganisms, such as viruses, bacteria, fungi, and such like.

The carrier(s) can be a solvent or dispersion medium including, without limitation, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, and liquid polyethylene glycol, and the like, or a combination thereof), one or more vegetable oils, or any combination thereof, although additional pharmaceutically-acceptable components may be included.

5 Proper fluidity of the pharmaceutical formulations disclosed herein may be maintained, for example, by the use of a coating, such as *e.g.*, a lecithin, by the maintenance of the required particle size in the case of dispersion, by the use of a surfactant, or any combination of these techniques. The inhibition or prevention of the action of microorganisms can be brought about by one or more antibacterial or antifungal
10 agents, for example, without limitation, a paraben, chlorobutanol, phenol, sorbic acid, thimerosal, or the like. In many cases, it will be preferable to include an isotonic agent, for example, without limitation, one or more sugars or sodium chloride, or any combination thereof. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example without limitation,
15 aluminum monostearate, gelatin, or a combination thereof.

While systemic administration is contemplated to be effective in many embodiments of the invention, it is also contemplated that formulations of the disclosed drug delivery compositions may be suitable for direct injection into one or more organs, tissues, or cell types in the body. Administration of the disclosed compositions may be
20 conducted using suitable means, including those known to the one of ordinary skill in the relevant medical arts. For example, the chemotherapeutic agents disclosed herein may be administered using any method as conventionally employed in the medical arts. In particular embodiments, the disclosed chemotherapeutic agents, and/or their pro-drug forms, may be formulated using one or more pharmaceutical buffers, vehicles, or diluents,
25 and intended for administration to a mammal through a suitable route.

The pharmaceutical formulations disclosed herein are not in any way limited to use only in humans, or even to primates, or mammals. In certain embodiments, the methods and compositions disclosed herein may be employed using avian, amphibian, reptilian, or other animal species. In preferred embodiments, however, the compositions of the present
30 invention are preferably formulated for administration to a mammal, and in particular, to humans, in a variety of diagnostic, therapeutic, and/or prophylactic regimens. The compositions disclosed herein may also be provided in formulations that are acceptable for veterinary administration, including, without limitation, to selected livestock, exotic or

domesticated animals, companion animals (including pets and such like), non-human primates, as well as zoological or otherwise captive specimens, and such like.

BRIEF DESCRIPTION OF THE DRAWINGS

For promoting an understanding of the principles of the invention, reference will now be made to the embodiments, or examples, illustrated in the drawings and specific language will be used to describe the same. It will, nevertheless be understood that no limitation of the scope of the invention is thereby intended. Any alterations and further modifications in the described embodiments, and any further applications of the principles of the invention as described herein are contemplated as would normally occur to one of ordinary skill in the art to which the invention relates.

The following drawings form part of the present specification and are included to demonstrate certain aspects of the present invention. The invention may be better understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements, and in which:

FIG. 1A and FIG. 1B illustrate exemplary mitochondrial-destroying warhead delivery compounds useful in the practice of the present invention. In particular, MP-MUS (N,N-bis(2-chloroethyl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)propanamide)/P⁺-MUS (I) (4-(1-[bis(2-chloroethyl)carbamoyl]ethyl)-1-methylpyridin-1-ium) are illustrated: ;

FIG. 2A and FIG. 2B show the *in silico* modeling of MAO substrate specificity. FIG. 2A **I and II** show the structures of 'perfect' substituted MPTP analogues that have high MAO-A **I**) or MAO-B **II**) specificity, with enzyme pocket contours. FIG. 2A **III** shows MP-MUS (I) and FIG. 2B shows the compound when docked within the MAO-B pocket;

FIG. 3 shows the MAO-catalyzed oxidation of resorufin-aminopropyl ether to resorufin;

FIG. 4 shows the MAO-catalyzed oxidation of the inactive SN38-aminopropyl ether form to its active SN38 metabolite;

FIG. 5 illustrates an exemplary synthetic scheme for chloroethyl-(methyl-1,2,3,6-tetrahydropyridin-4-yl)propanoyl) aziridinium;

FIG. 6A and FIG. 6B show the comparison of cellular toxicity of MP-MUS (I), Temozolomide and parental mustard at 24 hr. Shown are the effects of MP-MUS (I), Temozolomide and parental mustard on the growth of BT-111 cells, using two orthodox

techniques ($n = 3$, ± 1 Std. Deviation). FIG. 6A shows LDH growth and FIG. 6B shows mitochondrial XTT reduction;

FIG. 7A, FIG. 7B, FIG. 7C, and FIG. 7D demonstrate that the mitochondrial membrane potential was reduced by more than a third in the presence of 12 μ M MP-MUS(I) for 24 hours. 90% of the signal was conserved when cells were coincubated with the MAO-B inhibitor Segiline, implicating prodrug maturation as a likely targeting mechanism;

FIG. 8A, FIG. 8B and FIG. 8C demonstrate that MP-MUS (I) altered mitochondrial protein levels in glioma cells;

FIG. 9A, FIG. 9B, FIG. 9C, FIG. 9D, FIG. 9E and FIG. 9F show illustrative embodiments of the invention, and in particular, the measurement and quantitation of DNA breaks in BT-111 cells;

FIG. 10A and FIG. 10B show the %Cell protein in two cultures of primary GBM exposed to [APE-SN38], in the absence and presence of 2 μ M selegiline. Selegiline-treated cells, \circ , were measured in 3 wells at each concentration, and cells treated with only APE-SN38, \bullet , were measured in 6 wells. Error bars are the SEM at each APE-SN38 concentration. Protein was measured using the BCA/SDS method (Bicinchoninic acid (BCA) Protein Assay Kit with 0.1% sodium dodecyl sulfate detergent, (Thermo Fisher Scientific Inc., Rockford, IL USA; Cat#23235);

FIG. 11A and FIG. 11B show the %Cell protein in two cultures of primary GBM exposed to [APE-SN38], in the absence and presence of 2 μ M selegiline. Selegiline-treated cells, \circ , were measured in 3 wells at each concentration, and cells treated with only APE-SN38, \bullet , were measured in 6 wells. Error bars are the SEM at each APE-SN38 concentration. Protein was measured using the BCA/SDS method described in the legend of FIG. 10A and FIG. 10B;

FIG. 12 shows selegiline protected BT-111 and BT115 GBM cultures from cell death;

FIG. 13A and FIG. 13B show schematic representations of the conversion of MP-MUS to the active charged form, which crosses the mitochondrial membrane and the resulting 1000-fold concentration within the mitochondria;

FIG. 14 shows an illustrative schematic synthesis of APE-SN-38;

FIG. 15 shows the nuclear magnetic resonance (nmr) spectrum for APE-SN-38;

FIG. 16 shows the nmr spectrum for MP-MUS;

FIG. 17 shows an overview of an entire “family” of MP-MUS-based multicomponent compounds useful in the practice of the present invention;

FIG. 18 illustrates exemplary combination/permutational variants of MP-MUS multicomponent compounds including those with substitutions of the tetrahydropyridine ring, wherein R₁, R₂, R₃, R₅, and R₆ can include, but are not limited to, halogen, hydroxy, oxo, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkoxy, alkylthio, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, and heterocyclealkyl, as well as, -NRaRb, -NRaC(=O)Rb, -NRaC(=O)NRaNRb, -NRaC(=O)ORb, -NRaSO₂Rb, -C(=O)Ra, C(=O)ORa, -C(=O)NRaRb, -OC(=O)NRaRb, -ORa, -SRa, -SORa, -S(=O)₂Ra, -OS(=O)₂Ra, and -S(=O)₂ORa. In addition, each of the substituents listed above may be further substituted with one or more of the above substituents, such that the substituent comprises a substituted alky, substituted aryl, substituted arylalkyl, substituted heterocycle, or substituted heterocyclealkyl. Ra and Rb in this context may be the same or different and, independently, hydrogen, alkyl, haloalkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

FIG. 19A, FIG. 19B, FIG. 19C, FIG. 19D, FIG. 19E, FIG. 19F, FIG. 19G, FIG. 19H, FIG. 19I and FIG. 19J illustrate exemplary combination/permutational variants of the linkers in MP-MUS bifunctional compounds in accordance with one aspect of the present invention;

FIG. 20 illustrates an exemplary *N*-substituted-3-chloropropyl amine for conversion of drugs into MAO sensitive pro-drugs in accordance with one aspect of the present invention. Essentially any conventional drug, which has an active alcohol or thiol can be converted into a pro-drug that can only become converted into the active drug form following the enzymatic action of MAO on the resulting ether or thioether. The size/hydrophobicity of the bottom of the substrate binding pockets of MAO-A and MAO-B will confer selectivity towards the substrates;

FIG. 21A and FIG. 21B show illustrative *N*-substituted-3-chloropropyl amines for use in the conversion of selected therapeutic compounds into MAO-sensitive pro-drugs suitable for use in the practice of the present invention. FIG. 21A shows illustrative alcohols, while FIG. 21B shows illustrative thiols; Substituents R₁, R₂ and R₃ include, but are not limited to, halogen, hydroxy, oxo, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkoxy, alkylthio, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, and heterocyclealkyl, as well as, -NRaRb, -NRaC(=O)Rb,-

NRaC(=O)NRaNRb, -NRaC(=O)ORb --NRaSO₂Rb, -C(=O)Ra, -C(=O)ORa, -C(=O)NRaRb, -OC(=O)NRaRb, -ORa, -SRa, -SORa, -S(=O)₂Ra, -OS(=O)₂Ra and -S(=O)₂ORa.

FIG. 22A, FIG. 22B, FIG. 22C and FIG. 22D show illustrative existing
5 chemotherapeutic drugs that can be converted to MAO-sensitive pro-drugs in accordance with the methods of the present invention;

FIG. 23A, FIG. 23B, FIG. 23C, FIG. 23D and FIG. 23E show MAO-A and MAO-B activity of various MPTP derivatives useful in the practice of the present invention;

10 **FIG. 24A and FIG. 24B** show the effects of 24 hour MP-MUS treatment. A statistically-significant drop in tumor volume, about 50%, was observed;

FIG. 25 shows that the lumps are tumor. The lumps were extracted and minced, placed in cell culture media, one observes a little bit of the lump is full of GBM, which grow out of the lump onto the bottom of the cell culture well;

15 **FIG. 26A and FIG. 26B** show GBM from untreated and MP-MUS treated tumors. While the untreated cells appeared just like parental BT111, the MP-MUS treated cells were in poor condition, as evidenced by a lot of cell debris (even though they had already been washed);

FIG. 27 shows the plot of tumor size in the treated and untreated mice, error bars
20 are SEM. Statistical difference in on the top, first $p < 0.05$, the 0.005 and finally < 0.0005 ;

FIG. 28 show a different plot (untreated minus treated average) of the data. The shape of the curve suggests that the tumor shrunk by 60% after the first injection, then growth in MP-MUS cells was less than 50% the untreated rate; and

FIG. 29 shows the distribution in tumor size in the two mouse populations. Two
25 mice were cured, and all MP-MUS-treated mice were below the mean size of the untreated animals. 90% of the treated mice tumors are less that the smallest untreated tumor. The distribution of the untreated mice is Gaussian (i.e. normal), but the biggest one in the MP-MUS treated makes it non-Gaussian.

30 DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Illustrative embodiments of the invention are described below. In the interest of clarity, not all features of an actual implementation are described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the developers'

specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.

5

DESIGN CRITERIA FOR GLIOMA-SPECIFIC DRUGS

Designing a drug that specifically kills gliomas *via* the generation of a mitochondrial-accumulative toxin requires three main criteria.

First, the drug must have a toxic “warhead” that will destroy mitochondria
10 (targeting mtDNA and mtRibosomal RNA).

Second, the drug must have a high MAO-B/MAO-A specificity ratio, so that gliomas, and not ordinary cells, are the primary target.

Third, the drug must possess intrinsic “druglikeness” and be able to cross the blood brain barrier.

15 Druglikeness is a calculated pharmaceutical scale, that is derived by comparing structures of potential drug compounds with know compounds that have useful pharmaceutical properties (Slimak, 2010; Gimenez *et al.*, 2010; Lajiness *et al.*, 2004; Lipinski *et al.*, 2001; Lipinski *et al.*, 1997; Verber *et al.*, 2002).

20 LEVELS OF MAO A AND MAO-B ENZYME IN CANCER CELLS

The development of MP-MUS as an exemplary chemotherapeutic in the present invention was based on the well-known ability of the compound MPTP to be bio-converted into the mitochondrial targeting cationic MPP⁺. Based on this work, variants of MPTP, which have been shown to have differential levels of bioconversion by MAO-A and MAO-
25 B, can now be selectively synthesized that have MAO-A and/or MAO-B specificity. For instance, high levels of expression of MAO-A enzyme have been observed in high-grade prostate carcinoma (True *et al.*, 2006). A comparison of 469 benign and 889 cancerous samples demonstrated that MAO-A protein expression was elevated in cancerous epithelium relative to benign secretory epithelium ($P < 0.0001$), and MAO-A expression
30 was significantly elevated in Gleason 4 or 5 samples relative to Gleason 3 samples ($P < 0.0001$). MAO-B activity has been demonstrated to be significantly higher in glioblastoma multiformes, low-grade astrocytomas, and in anaplastic astrocytomas than in postmortem control brains ($p < 0.01$) (Gabilondo *et al.*, 2008).

ANALOGS OF MP-MUS BASED ON ANALOGS OF MPTP

A number of MPTP analogs have been prepared, and their MAO A/B substrate properties investigated. The crystal structures of human MAO-A and MAO-B are known, and that knowledge permits modeling studies and rational drug design. It has been found that: 1) the double bond at positions 4 and 5 of the tetrahydropyridine ring is essential for compounds to be MAO substrates; 2) substituents at the C-4 and N-1 positions of the tetrahydropyridine ring favorably increase the kinetics of MAO-A/MAO-B oxidation, and alter the specificity of the substrate towards the two enzymes (typically, the placement of an alkyl group anywhere else in the tetrahydropyridine ring diminishes reactivity towards both MAO-A and MAO-B, but differentially alters the substrate specificity toward the two enzymes); 3) substitution at the N-1 position is limited to small substituents (the N-methyl group appears to be the ideal size, while substituents such as N-H, N-methyl, N-ethyl and N- α -hydroxyethyl are less favorable; 4) the phenyl ring is not necessary for compounds to be MAO substrates, and replacement of the phenyl ring by a 1-methyl-2-pyrrolyl-, a benzyl-, or a phenoxy- group enhances MAO reactivity (*e.g.*, the 4-cyclohexyl analog has been shown to be as effective of a substrate as MPTP); and 5) *para*-substituents on the phenyl ring produce steric hindrance unfavorable to reactivity, while *ortho*- and *meta*-substituents may have stabilizing interactions within the active site increasing reactivity.

MP-MUS VARIANTS

The present invention is extendable to a variety of chemotherapeutic MAO-A and MAO-B compounds that have the generalized structure shown in FIG. 17. The MP-MUS “parental” compound comes in three functionalized blocks; an N-substituted tetrahydropyridine (targeting moiety or “seeker”), a linking group that is sculpted to fit the enzymatic pockets of either MAO-A and/or MAO-B and a therapeutic moiety (or “warhead”) that has the property of causing damage to biological macromolecules like proteins, DNA and RNA or to act as specific inhibitors to enzymes or transport or signaling systems vital to life.

EXEMPLARY DEFINITIONS

The terms “about” and “approximately” as used herein, are interchangeable, and should generally be understood to refer to a range of numbers around a given number, as well as to all numbers in a recited range of numbers (*e.g.*, “about 5 to 15” means “about 5

to about 15” unless otherwise stated). Moreover, all numerical ranges herein should be understood to include each whole integer within the range.

The term “e.g.,” as used herein, is used merely by way of example, without limitation intended, and should not be construed as referring only those items explicitly
5 enumerated in the specification.

As used herein, the term “carrier” is intended to include any solvent(s), dispersion medium, coating(s), diluent(s), buffer(s), isotonic agent(s), solution(s), suspension(s), colloid(s), inert(s) or such like, or a combination thereof, that is pharmaceutically acceptable for administration to the relevant animal. The use of one or more delivery
10 vehicles for chemical compounds in general, and chemotherapeutics in particular, is well known to those of ordinary skill in the pharmaceutical arts. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the diagnostic, prophylactic, and therapeutic compositions is contemplated. One or more supplementary active ingredient(s) may also be incorporated into, or administered in
15 association with, one or more of the disclosed chemotherapeutic compositions.

As used herein, the term “patient” (also interchangeably referred to as “host” or “subject”) refers to any host that can receive one or more of the pharmaceutical compositions disclosed herein. Preferably, the subject is a vertebrate animal, which is intended to denote any animal species (and preferably, a mammalian species such as a
20 human being). In certain embodiments, a “patient” refers to any animal host including without limitation any mammalian host. Preferably, the term refers to any mammalian host, the latter including but not limited to, human and non-human primates, bovines, canines, caprines, cavines, corvines, epines, equines, felines, hircines, lapines, leporines, lupines, murines, ovines, porcines, ranines, racines, vulpines, and the like, including
25 livestock, zoological specimens, exotics, as well as companion animals, pets, and any animal under the care of a veterinary practitioner. A patient can be of any age at which the patient is able to respond to inoculation with the present vaccine by generating an immune response. In particular embodiments, the mammalian patient is preferably human.

The phrase “pharmaceutically-acceptable” refers to molecular entities and
30 compositions that preferably do not produce an allergic or similar untoward reaction when administered to a mammal, and in particular, when administered to a human. As used herein, “pharmaceutically acceptable salt” refers to a salt that preferably retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects. Examples of such salts include, without limitation, acid addition salts formed with

inorganic acids (*e.g.*, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like); and salts formed with organic acids including, without limitation, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pantoic (pantoic) acid, alginic acid, naphthoic acid, polyglutamic acid, naphthalenesulfonic acids, naphthalenedisulfonic acids, polygalacturonic acid; salts with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, and the like; salts formed with an organic cation formed from *N,N'*-dibenzylethylenediamine or ethylenediamine; and combinations thereof.

“Protein” is used herein interchangeably with “peptide” and “polypeptide,” and includes both peptides and polypeptides produced synthetically, recombinantly, or *in vitro* and peptides and polypeptides expressed *in vivo* after nucleic acid sequences are administered into a host animal or human subject. The term “polypeptide” is preferably intended to refer to any amino acid chain length, including those of short peptides from about 2 to about 20 amino acid residues in length, oligopeptides from about 10 to about 100 amino acid residues in length, and longer polypeptides including from about 100 amino acid residues or more in length. Furthermore, the term is also intended to include enzymes, *i.e.*, functional biomolecules including at least one amino acid polymer. Polypeptides and proteins of the present invention also include polypeptides and proteins that are or have been post translationally modified, and include any sugar or other derivative(s) or conjugate(s) added to the backbone amino acid chain.

As used herein, the term “substantially free” or “essentially free” in connection with the amount of a component preferably refers to a composition that contains less than about 10 weight percent, preferably less than about 5 weight percent, and more preferably less than about 1 weight percent of a compound. In preferred embodiments, these terms refer to less than about 0.5 weight percent, less than about 0.1 weight percent, or less than about 0.01 weight percent.

The term “glioma,” as used herein, includes, without limitation, tumors that arise from non-neuronal cells of the central nervous system, such as from glial and related cells, such as ependymal cells, astrocytes, oligodendrocytes, and such like. The term glioma comprises disease conditions such as, without limitation, ependymomas, astrocytomas (and in particular, glioblastomas), oligodendrogliomas, oligoastrocytomas, and other gliomas of mixed origin, *e.g.*, those originating from more than one type of cell, including cells of astrocytes, ependymal cells and/or oligodendrocytes. The affected tissue may include any

one or more portions of the nervous system, such as, without limitation, the brain, spinal cord tissue, and such like.

The term “pharmaceutically acceptable salt” as used herein refers to a compound of the present disclosure derived from pharmaceutically acceptable bases, inorganic or organic acids. Examples of suitable acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, trifluoroacetic and benzenesulfonic acids. Salts derived from appropriate bases include, but are not limited to, alkali such as sodium and ammonia.

As used herein, the terms “prevent,” “preventing,” “prevention,” “suppress,” “suppressing,” and “suppression” as used herein refer to administering a compound either alone or as contained in a pharmaceutical composition prior to the onset of clinical symptoms of a disease state so as to prevent any symptom, aspect or characteristic of the disease state. Such preventing and suppressing need not be absolute to be deemed medically useful.

As used herein, the terms “treat,” “treating,” and “treatment” refer to the administration of one or more compounds (either alone or as contained in one or more pharmaceutical compositions) after the onset of clinical symptoms of a disease state so as to reduce, or eliminate any symptom, aspect or characteristic of the disease state. Such treating need not be absolute to be deemed medically useful. As such, the terms “treatment,” “treat,” “treated,” or “treating” may refer to therapy, or to the amelioration or the reduction, in the extent or severity of disease, of one or more symptom thereof, whether before or after its development afflicts a patient.

As used herein, the phrase “in need of treatment” refers to a judgment made by a caregiver such as a physician or veterinarian that a patient requires (or will benefit in one or more ways) from treatment. Such judgment may be made based on a variety of factors that are in the realm of a caregiver's expertise, and may include the knowledge that the patient is ill as the result of a disease state that is treatable by one or more compound or pharmaceutical compositions such as those set forth herein.

The term “for example” or “e.g.,” as used herein, is used merely by way of example, without limitation intended, and should not be construed as referring only those items explicitly enumerated in the specification.

In accordance with long standing patent law convention, the words “a” and “an” when used in this application, including the claims, denote “one or more.”

EXAMPLES

5 The following examples are included to demonstrate illustrative embodiments of the invention. It should be appreciated by those of ordinary skill in the art that the techniques disclosed in these examples represent techniques discovered to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of ordinary skill in the art should, in light of the present
10 disclosure appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1 - GLIOMA-SPECIFIC DRUG DESIGN (I)

15 Using the aforementioned criteria, the inventors have designed and synthesized a novel pro-drug, the activated form of which has specifically designed to kill mammalian gliomas. This pro-drug, designated MP-MUS (I), is activated by mammalian MAO-B enzyme to form P⁺-MUS (I), an acylation agent, whose ionic charge and inherent lipophilicity results in mitochondrial accumulation of the agent. This compound has been
20 successfully tested in primary human glioblastoma cells, and shown to possess potent anti-cancer properties *in vivo*.

1. MP-MUS (I) IS A MITOCHONDRIAL-SPECIFIC “SMART BOMB” FOR CANCER TREATMENT.

25 **Design of a MAO-B specific “warhead” compound.** The MAO-B-mediated conversion of the 1-methyl-1,2,3,6-tetrahydropyridine moiety into a 1-methyl-pyridium cation facilitates mitochondrial targeting of the novel therapeutics described herein (FIG. 1A).

30 The “warhead” of this “smart-bomb” chemotherapeutic is nitrogen mustard, which has been used in the treatment of cancer since the 1940s. Cyclization of *N*-chloroethane into reactive aziridine (an ammonium-based, three-membered ring), facilitates acylation of DNA/RNA bases, and particularly the N-7 group on guanine.

Traditional nitrogen mustards are subject to hydrolysis, and have a half-life of about 10 to 90 min at neutral pH (Price, 1968). In an ideal ‘warhead’ the reactivity of the

‘warhead’ will be tuned to the bioconversion of the gliomal MAO-B so that as large a part of ‘warhead’ activity as possible occurs within the mitochondria of the MAO-active, target cancer cell.

The inventors have designed a less-reactive nitrogen mustard that persists in the human body long enough to be activated by gliomal MAO-B, but is not a MAO-B suicide substrate, due to the incorporation of a carbonyl oxygen (see *e.g.*, **FIG. 1B**. The carbonyl group is electron-withdrawing, and so it destabilizes the aziridine form, and produces two desirable effects: firstly, only a small fraction of the pro-drug/drug will be reactive at any one time, and secondly, the destabilized aziridine is more reactive than ‘typical’ nitrogen mustards.

Stabilization of aziridine affords the compound time to undergo the bioconversion by MAO-B in the glioma, and ensures the potency of the mature, mitochondrially-targeting active compound.

Additionally, it is possible that oxazol is formed *via* elimination of HCl and cyclization of immine/ethlychloride, which would also increase the stability of the acylating group. .

Development of Drug Targeting System. The rate at which MPTP is preferentially oxidized by MAO-B, in comparison to MAO-A, is typically presented as the ratio of the two K_{cat} ’s; where K_{cat} is the maximum catalytic activity divided by the K_m (Heikkila *et al.*, 1988). The MAO-B/MAO-A ratio is on the order of 4 to 10, depending on the particular buffering conditions (see *e.g.*, Heikkila *et al.*, 1988; Castagnoli *et al.*, 1999; Nimkar *et al.*, 1999; Palmer *et al.*, 1997; Castagnoli *et al.*, 1997). Moreover, the kinetics of MAO-B/MAO-A for a wide range of different substitutions on the two ring-systems of MPTP have been widely investigated (see *e.g.*, Castagnoli *et al.*, 1999; Nimkar *et al.*, 1999; Palmer *et al.*, 1997; Castagnoli *et al.*, 1997).

Using the available information on the kinetics of different MPTP analogues (*e.g.*, Palmer, 1998), the inventors have designed a pair of *in silico* ‘ideal’ MAO-A- and MAO-B-specific MPTP analogs (see **FIG. 2A**). The substrate binding sites of MAO-A/B can be divided into three regions: an amine-binding pocket around the FAD moiety, **P1’**, and a ‘selectivity void,’ which consists of two compartments, **P2’** and **P3’** (following the terminology of Efang and Boudreau, 1991). **P2’** is both larger and nearer to the FAD site, in MAO-A, whereas **P3’** is larger in MAO-B (Flamand *et al.*, 2010; Castagnoli *et al.*,

1999; Nimkar *et al.*, 1999; Palmer *et al.*, 1997; Castagnoli *et al.*, 1997; Palmer, 1998; Efange and Boudreau, 1991; Binda *et al.*, 2007) (see FIG. 2A).

MP-MUS (I) was designed so that it would fit into the pocket of human MAO-B, *in silico*. FIG. 2B shows the fit of MP-MUS (I) into the pocket of human MAO-B; (structure
5 identification code, 2V60; Binda *et al.*, 2007).

‘Druglikeness’. As noted above, candidate drug compounds to treat gliomas should possess “druglikeness,” that is, they should possess properties that are predicted to lead to oral bioavailability, to readily cross the blood brain barrier, and to have adequate chemical and metabolic stability, and minimal toxic effects. The Molinspiration property
10 calculator (Slimak, 2010) was used to examine the properties of both the pro-drug, MP-MUS(I), and the mature active “killer” compound, P⁺-MUS (I). These data are shown in **Table 1**.

TABLE 1

‘Druglikeness’ of MP-MUS (I)/P ⁺ -MUS (I) and MPTP/MPP ⁺							
Rule	Parameter	MP-MUS	MPTP	P ⁺ -MUS	MPP ⁺	MP	P ⁺
Lipinski’s	LogP	2.24	2.33	-3	-2.73	>1-5<	<<0
	MW	293	173	290	170	<450	
	H-Bond acceptors	3	1	3	1	≤10	
	H-Bond donors	0	0	0	0	≤5	
Veber’s	Rotatable bonds	6	1	6	1	>6-10<	
	Mol Polar SA	23.6	3.24	24.2	3.9	>15-40<	

15

A widely-used model for estimating druglikeness is known in the art as Lipinski’s ‘Rule of Five’ (see *e.g.*, Gimenez *et al.*, 2010; Lajiness *et al.*, 2004; Lipinski *et al.*, 2001; and Lipinski *et al.*, 1997). Lipinski’s rule states that, in general, an orally-active drug should not violate more than one of the following criteria: 1) not more than five hydrogen
20 bond donors (*i.e.*, nitrogen or oxygen atoms with one or more hydrogen atoms); 2) not more than ten hydrogen bond acceptors (*i.e.*, nitrogen or oxygen atoms); 3) a molecular mass that is less than 500 Daltons, and 4) an octanol-water partition coefficient log *P* not greater than five.

The ability of MP-MUS (I) to enter the brain, and for P⁺-MUS (I) to be retained in
25 the brain, unable to re-cross the blood brain barrier, can be inferred from the partition coefficient, log *P* (van de Waterbeemd *et al.*, 1998; Verber *et al.*, 2002; Lajiness *et al.*, 2004; Lipinski *et al.*, 2001; Lipinski *et al.*, 1997). The pro-drug has the correct


lipophilicity to cross membranes, but is soluble enough in aqueous media to be supplied in oral form (van de Waterbeemd *et al.*, 1998). Cationic P⁺-MUS (I) can cross the mitochondrial membrane (driven by the $\Delta\Psi$), has high solubility, and will not crystallize out of solution in the cellular matrix.

MP-MUS (I) also meets the “Veber rules” (Veber *et al.*, 2002) for rotatable bond and polar surface area (see Table 1), and possesses significant “druglikeness” such that the mature drug compound, P⁺-MUS (I), accumulates within the mitochondria (driven by the membrane potential) at a concentration that can be as much as 1000× greater than that present in the cytosol.

EXAMPLE 2 - GLIOMA-SPECIFIC DRUG DESIGN (2)

APE-SN38, a topoisomerase-specific “smart bomb” for cancer treatment.

Albers and co-workers (2007) demonstrated that aminopropyl ethers were labile in the presence of MAO, and it is this property that led to the development of a novel MAO-A/MAO-B assay system. 7-(3-aminopropoxy)-3H-phenoxazin-3-one is oxidized by MAO (*via* iminium and aldehyde intermediates), to release the fluorescent compound, resorufin, and propanal *via* a β -elimination reaction (FIG. 3). Utilizing the same iminium and aldehyde intermediates, followed by a β -elimination reaction, it should therefore be possible to convert existing pharmaceutical compounds having a tertiary/phenolic alcohol group into MAO-specific biotransformable drugs. For example, SN38 is the active metabolite of the pro-drug, camptothecin, and chemotherapeutic, irinotecan (Yao *et al.*, 2011). To demonstrate the facility of utilizing extant therapeutic compounds having tertiary/phenolic alcohol groups in the methods described herein, the inventors exploited SN38 to develop a new “warhead” targetable therapeutic. In illustrative embodiments, the phenolic alcohol of position 10, ring A, of SN38 camptothecin structure was modified by the present inventors with propylamine to form the compound 7-ethyl-10-(3-aminprop)-oxy-camptothecine:



According to IUPAC nomenclature rules, the systematic name of the resulting compound can also be stated as either: (*S*)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1*H*-pyrano[3',4':6,7]-indolizino[1,2-*b*]quinolin-9-oxy-propylamine, or (19*S*)-7-(3-aminopropoxy)-10,19-diethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.01^{5,20}] henicos-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione. In the present example, this compound was tested for its suitability as a therapeutic moiety in the methods of the invention.

10 MATERIALS AND METHODS

Primary GBM. Primary human glioblastoma cells were obtained from surgical theater, and subsequently grown in MEM with penicillin/streptomycin and 10% FBS (Invitrogen corporation, Carlsbad, CA USA). After 2 or more weeks of growth and splitting, 250 μ L of resulting cells (at a density of 1×10^4 cells per mL) were plated into 96-well microtiter plates (Corning, NYC, NY, USA, and grown to confluence by incubation at 37°C for at least 24 hr.

After 24 hrs, cells were treated with 20 μ L/mL of ethanol, containing either the test drugs, inhibitors, or no additives (internal controls).

Selegiline (L-deprenyl) (Sigma-Aldrich, St. Louis, MO, USA) was used as a specific inhibitor of MAO-B at concentrations of 2-10 μ M, based on published reports (Hao *et al.*, 1995), and was used at least an eight-fold higher concentration (2 μ M = 8*0.25 μ M) based upon the approximate eight-fold higher expression level of MAO-B in GBM than in regular cells.

Epifluorescence Microscopy. Signals were acquired using a Nikon Eclipse TE2000-E fluorescent microscope equipped with a CoolSnap ES digital camera system (Roper Scientific, Tucson, AZ, USA) containing an CCD-1300-Y/HS 1392 \times 1040 imaging array cooled by a Peltier device.

Images were recorded using Nikon NIS-Elements software version 3.2 Nikon Instruments Inc. Melville, NY, USA), and images were stored as jpg2000 files. Images were analyzed using the same NIS-Elements software.

Cell Viability Measurements. Cells were incubated with μM Hoechst 33258 (Cat#H1398) in the presence and absence of 500 nM Mitotracker® Red (Cat#M22425), or the reactive oxygen species specific reagent H_2DCFDA (6-carboxy-2',7'-dichlorodihydro fluorescein diacetate) for 1 hr (reagents obtained from Invitrogen (Eugene, OR, USA). The buffer used was 5 mM glucose/3 mM Tris/30 mM HEPES/10 mM NaCl buffer (pH 7.4) at 37°C.

Fixing, Washing and Permeabilization of Cells. Cells were fixed in ice-cold 2% paraformaldehyde/phosphate buffered saline (PFA) for 2-24 hr, and cells were washed in 11.9 mM phosphate, 137 mM NaCl and 2.7 mM KCl (**PBS**; Fisher Bioreagents, Fair Lawn, New Jersey, USA) and then permeabilized in three washes of PBS + 0.1% Triton X-100 (Sigma Aldrich, St. Louis, MO, USA).

Viability Cut-off. Cells were counted at 4 \times magnification, and cells were deemed to be non-viable if they had Hoechst signals >5 times the level found in untreated cells.

ddTUNEL. A *Tdt* reaction buffer was prepared daily diluting a stock solution of 125 mM Tris-HCl, 1 M sodium cacodylate, 1.25 mg/mL BSA, pH 6.6 by 1:5 and diluting 1:25 a 25 mM cobalt chloride stock solution. The sample was twice washed in this solution and then $\approx 50\ \mu\text{L}$ of reaction buffer containing 20 units/mL of *Tdt* and 250 nM of labeled-*ddUTP* was applied to each of the sections, which were then incubated in a humidified box overnight at room temperature or for 2 hours at 37°C. Roche Biotin-16-*ddUTP* (Roche Diagnostics, Branford, CT, USA) was used throughout and was visualized using Texas-Red labeled Avidin (Baskin *et al.*, 2010a; Baskin *et al.*, 2010b).

Antibody Labeling. Anti-mitochondrial ribosomal protein L11 rabbit antibody (ab74285) and Anti-cytochrome c antibody (ab13575) were obtained from Abcam (Cambridge, MA, USA), and were visualized using labeled secondary antibodies; Alexa Fluor 594 goat anti-mouse IgG (A-11032) and Alexa Fluor 488 goat anti-rabbit IgG (A-11034) from Invitrogen. Permeabilized cells were blocked with 10% equine sera (Invitrogen) for 1 hr, washed in PBS/0.1% Triton X-100 and then incubated overnight with primary antibody (1:1000), washed twice in PBS/0.1% Triton X-100, incubated with the secondary's overnight and then washed twice more. DNA was stained using DAPI (Invitrogen) by incubation with 30 nM DAPI in PBS for 5 min, and then cells were washed

twice in PBS/0.1% Triton X-100. The wells were then filled with 100 μ L PBS/0.1% Triton X-100, and imaging performed.

XTT Assay. Mitochondrial function was assayed using the XTT (2,3-Bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide) mitochondrial and extramitochondrial dehydrogenases assay method (Berridge *et al.*, 2005; Huet *et al.*, 1992) Sigma-Aldrich, St. Louis, MO, USA). The medium was withdrawn from the cells that were then washed in 5 mM glucose/3 mM Tris/30 mM HEPES/10 mM NaCl buffer (pH 7.4) and treated with 0.5 mg/mL XTT in the same buffer for 1 hr at 37°C. The generated levels of formazan were read at 565-490 nm.

LDH Assay. After the XTT levels were determined the cells were washed using $2 \times 250 \mu$ L of 5 mM glucose/3 mM Tris/30 mM HEPES/10 mM NaCl buffer (pH 7.4). The levels of lactate dehydrogenase activity in the presence of detergent (Korzeniewski and Callewaert, 1983; Decker and Lohmann-Matthes, 1988) were then assayed in each well (Corning, NYC, NY, USA). The final assay mixture contained 100 μ L of 110 mM lactate, 3.35 mM NAD^+ , 350 μ M resazurin (Sigma-Aldrich, St. Louis, MO, USA), and 2.2 units/mL of diaphorase in 5 mM glucose/3 mM Tris/30 mM HEPES/10 mM NaCl buffer (pH 7.4) and 0.45% TritonX-100. The resorufin formed was measured over the course of 15 min in a plate reader using at 530/25 nm excitation (ex) and 590/35 nm emission (em). The rates at which resorufin was formed were proportional to the levels of LDH, and consequently, cell number (Korzeniewski and Callewaert, 1983; Decker and Lohmann-Matthes, 1988).

Protein Assay. Cell protein mass was measured using the Micro BCA Protein Assay Kit from Thermo Scientific (Thermo Fisher Scientific Inc., Waltham, MA, USA), supplemented with 1% sodium dodecyl sulfate to solubilize all protein.

Synthesis of MP-MUS

The starting compound, methyl-1,2,3,6-tetrahydropyridin-4-yl-propanoic acid, was synthesized in three steps using the Wittig-Horner reaction, followed by lithium aluminum hydride reduction of the piperidine ring and ester hydrolysis of the ester, based on the published methodology (Differding and Ghosez, 1985).

Synthesis of ethyl (1-methylpiperidin-4-ylidene)propanoate (1)

N-methyl-4-piperidone (0.5 gm, 4.42 mmol) was dissolved in anhydrous ether (5 mL) in a dry flask under argon and triethyl-2-phosphonopropionate (1.58 gm,

6.63 mmol) was added, followed by addition of sodium hydride (0.12 gm, 4.86 mmol) at 0°C for 10 min. The reaction mixture was heated at reflux (50°C) for 4 hr when thin layer chromatographic (TLC) analysis demonstrated that no starting material remained. Solvent was evaporated under vacuum, the residue was dissolved in dichloromethane (50 mL) and the solution washed with water (3 × 50 mL). The organic phase was dried (MgSO₄), evaporated to dryness and purified on a silica gel column using 2% methanol in dichloromethane. The pure compound **1** (0.54 gm) was obtained in 62% yield. ¹H NMR **1** (CDCl₃) δ: 4.15 (m, 2H), 2.41-2.36 (m, 7H), 2.15 (s, 3H), 2.00 (t, J = 7.2, 4H), 1.19 (t, J = 7.6, 3H). MS: (M+1) calculated 198.27, found 198.35.

Synthesis of Ethyl (1-methyl-1,2,3,6-tetrahydropyridin-4-yl)propanoate (**2**)

Compound **1** (0.4 gm, 2.02 mmol) was dissolved in anhydrous THF (5 mL) in a dry flask under argon atmosphere at -68°C for 10 min. Lithium aluminum hydride (3 mL, 3.04 mmol) was added dropwise into this mixture and stirred for 1 hr. The reaction mixture was warmed to room temperature and again stirred for 1 hr, when TLC showed that no starting material remained. The reaction was quenched with 100 μL of NH₄Cl, filtered and evaporated under vacuum. The crude residue was dissolved in dichloromethane (50 mL) and washed with water (3 × 50 mL). The organic phase was dried and yielded the unsaturated ester **2** (~100% crude) which was directly saponified to acid. ¹H NMR **2** (CDCl₃) δ: 5.78 (t, J=7.1, 1H), 4.39 (m, 2H), 3.16 (m, 1H), 2.88 (d, 2H), 2.52 (m, 2H), 2.18 (s, 3H), 2.01 (t, J = 7.2, 2H), 1.21 (t, J=8.1, 3H), 1.1(d, 3H). MS: (M+1) calculated 198.27, found 198.33.

Synthesis of methyl-1,2,3,6-tetrahydropyridin-4-yl-propanoic acid (**3**)

Compound **2** (0.35 gm, 1.77 mmol) was dissolved in TFA (5 mL) and 2 mL of 1N NaOH solution was added into this mixture. The reaction mixture was heated at reflux (70°C) for 2 hr when TLC showed that no starting material remained. Solvent was evaporated under vacuum and crude product was dissolved in dichloromethane (50 mL) and washed with brine (3 × 50 mL). The organic phase was dried (MgSO₄), evaporated to dryness and the crude product was purified on a silica gel column and using 2% methanol in dichloromethane as eluent. This afforded product **3** as white color solid (0.24 gm, 80% yield). ¹H NMR **3** (CDCl₃) δ: 10.2 (bs, 1H), 5.72 (t, J=7.2, 1H), 3.19 (m, 1H), 2.85 (d, 2H), 2.50 (m, 2H), 2.18 (s, 3H), 2.03 (t, J = 7.1, 2H), 0.91 (d, 3H).

MS: (M+1) calculated 170.22, found 170.28.

Synthesis of chloroethyl-(methyl-1,2,3,6-tetrahydropyridin-4-yl) propanoyl aziridinium (4)

Compound **3** (0.23 gm, 1.36 mmol) was dissolved in anhydrous dichloromethane (5 mL) in a dry flask under argon atmosphere and Benzotriazolyloxytris (dimethylamino) phosphonium Hexafluorophosphate (Sigma-Aldrich, St. Louis, MO, USA) (0.9 gm, 2.04 mmol) was added, followed by addition of bis(2-chloroethyl)amine (0.36 gm, 2.04 mmol) at 0°C for 10 min. The reaction mixture was warmed to room temperature and stirred for 3 hr, when TLC showed that no starting material remained. Solvent was evaporated under vacuum and crude product was extracted with dichloromethane (50 mL) and washed with water (3 × 50 mL). The organic extracted was dried and evaporated. The crude product was purified on a silica gel column and using 2% methanol in dichloromethane as eluent to isolate **4** (0.27 gm) in 77% yield. MS: M+K, calculated 296.78, found 296.90. ¹H NMR **4** (DMSO-d₆) δ: 4.03 (m, 5H, CH₂ & ArH), 3.05 (m, 2H, CH₂), 2.78 (d, J = 10.5 Hz, 5H, CH₂, CH & ArCH₂), 1.23 (m, 10H, ArCH₂ & CH₃). The synthetic pathway is shown in FIG. 5.

EXAMPLE 3 - KILLING PRIMARY HUMAN GLIOBLASTOMA MULTIFORME CELLS *IN VITRO* USING MP-MUS(I).

1) Effect of MP-MUS (I) on cell growth and mitochondria. Primary glioma human cells, (internally coded as “BT-111”), were obtained for a (first) resection of a Glioblastoma Multiforme tumor, and grown in either 96-well microplate format or in slide tanks. Cells were incubated with three different drugs; the traditional treatment; temozolomide, nitrogen mustard, or MP-MUS (I). The effects on cell growth and mitochondrial function are shown in FIG. 6A and FIG. 6B in the presence of MP-MUS (I), the parental mustard and Temozolomide in primary GBM cells; BT-111. These results demonstrate that MP-MUS (I) was a potent glioma toxin, with an LD₅₀ 5-fold *lower* than the standard chemotherapeutic drug, temozolomide. Of particular interest was the differing effect observed on mitochondria for these two compounds. MP-MUS (I) abolished half of the mitochondrial complex activity at concentrations of ≈2 μM, whereas temozolomide caused an *increase* in the levels of mitochondria in BT-111 cells, at concentrations >10 μM.

Growth (in microplate wells for 24 or 48 hr) of cells treated either with test drug or the ethanol vehicle alone was assayed using the lactate dehydrogenase assay method and also with the XTT mitochondrial complex activity, assay. Data collected from treatment with the parent nitrogen mustard, (*bis*-(2-chloroethyl)-amine), showed that it was not significantly toxic at concentrations less than 100 μ M.

2) Effect of MP-MUS (I) on mitochondrial membrane potential ($\Delta\Psi$).

Mitochondrial targeting was confirmed using the $\Delta\Psi$ probe, Mitotracker® Red. BT-111 cells were treated with MP-MUS (I), 12 μ M for 24 hr with or without the addition of 10 μ M selegiline (Geha *et al.*, 2001); a MAO-B-specific inhibitor. Cells were then incubated with 500 nM Mitotracker® Red for 1 hr and after washing the living cells were imaged at x40 magnification in the wells of a 96-well plate (see FIG. 7A, FIG. 7B, FIG. 7C, and FIG. 7D). Selegiline had no effect on $\Delta\Psi$, but MP-MUS (I) lowered the signal to a statistically-significant 31%, a drop that was almost completely arrested by co-incubation with the MAO-B inhibitor selegiline.

3) Effect of MP-MUS (I) on mitochondrial proteins. To further demonstrate that the mitochondria was being targeted, the levels the mitochondrial matrix protein, L11, part of the mtRibosome and cytochrome *c*, found in the inter-membrane space, were each probed using specific antibodies, in cells, following either 24 or 48 hrs' incubation with MP-MUS (I) (see FIG. 8). It was evident that there was an increase in the levels of L11 (red), and cytochrome *c* (green), after only 24 hrs' incubation. Extending the incubation time to 48 hrs resulted in >95% cell death, with the remaining survivors extremely damaged.

The control cells showed both proteins co-localized in the cytosol. After 24-hr incubation with 10 μ M MP-MUS (I), cells had typical morphology, normal nuclei, but showed more mitochondrial protein. Extending the incubation to 48 hrs led to a loss of morphology, bloated nuclei, and a loss of defined mitochondria. Although the levels of L11 remained high, there was an almost complete loss of cytochrome *c*.

A paired sample underwent the same ligation following incubation with DNA polymerase/*d*NTP, so all overhanging ends were converted into blunt ends. The blue signals showed DAPI-stained DNA, while the red signals showed blunt-ended and total breaks (seen in FIG. 9, upper and lower panels). It was clear that MP-MUS (I) was extremely good at inducing DNA breaks, far more so than the conventional methylation

agent, temozolomide. Moreover, the vast majority of the damage was extra-nuclear, indicating that it was mitochondrial DNA that was the target. Additionally, overhanging ends were the most common type of break observed.

5 **EXAMPLE 4 -- KILLING PRIMARY HUMAN GLIOBLASTOMA MULTIFORME CELLS *IN VITRO* USING APE-SN38.**

Effect of APE-SN38 on cell growth; measured by protein levels and live cell counts.

Primary glioma human cells (referred to as “BT-111” and “BT-115” herein), were
10 obtained from resection of glioblastoma multiforme tumors from two separate patients, and grown in 96-well format.

Cells were incubated with a titration of APE-SN38 in the presence or absence of the MAO-B-specific inhibitor, selegiline, at 2 μ M using published methods (Geha *et al.*, 2001). Total cell protein mass was measured using the BCA/SDS method after a 24-hr
15 incubation, and find an LD₅₀ of \approx 50 μ M APE-SN38 in both primary cell cultures, but that the MAO-B inhibitor selegiline affords the cells almost complete protection (FIG. 10A and FIG. 10B), indicating MAO-B bioconversion.

Cell counts (of five wells at each concentration), were also used to establish the numbers of live cells at each concentration (FIG. 11A and FIG. 11B).

20 Cell death at high concentrations of APE-SN38 could be arrested by co-incubation with 2 μ M selegiline (see FIG. 12). FIG. 12 shows protected BT-111 and BT115 GBM cultures from cell death. The protection afforded was seen after 24 hrs’ incubation with APE-SN38. Cells were incubated for 24 hrs, then treated with Hoechst’s viability stain, and fixed.

25

EXAMPLE 5 -- SYNTHESIS OF APE-SN38

APE-SN38 was synthesized using the route of Albers, Rawls and Chang with 3-chloropropylamine (although *N*-R₁ substituted chloropropylamine is shown in the reaction scheme shown in FIG. 15).

30 **N-R₁,3** chloro-propylamine was Boc protected, to give the amine-protected, *tert*-butyl 3-chloropropyl N-carbamate (**1**). The Boc-protected derivative was used to generate the SN-38 (7-ethyl-10-hydroxycamptothecin) ether using K₂CO₃ in DMF. The product is an ether; 9-(Boc(R₁)aminopropoxy)7-ethyl-10-hydroxycamptothecin (**2**) was treated with trifluoroacetic acid to give the final product (wherein R₁ = H); (1*S*)-7-(3-aminopropoxy)-

10,19-diethyl-19-hydroxy-17-oxa-3,13-diazapentacyclohenicosa-1,2,4,5,7,10,15-heptaene-14,18-dione (**3**), and purified by HPLC.

The nmr spectrum of the final product, APE-SN38 ($R_1 = H$), is shown in FIG. 16.

5 EXAMPLE 6 – NMR SPECTRUM FOR MP-MUS

In DMSO the chloroethyl-(methyl-1,2,3,6-tetrahydropyridin-4-yl) propanoyl aziridinium (**4**) was the most common form observed. The proton nmr, recorded in DMSO-d₆, shows 22 H-signals of (**4**) (see FIG. 16).

¹H NMR **4** (DMSO-d₆) d: 4.03 (m, 5H, CH₂ and ArH), 3.05 (m, 2H, CH₂), 2.78 (d, 10 J = 10.5 Hz, 5H, CH₂, CH and ArCH₂), 1.23 (m, 10H, ArCH₂ and CH₃).

EXAMPLE 7 – EXEMPLARY SN-38-RELATED COMPOUNDS AND DERIVATIVES THEREOF.

Any chemotherapeutic that has requirement for either an alcohol or thiol for its action can be modified by being transformed into either an ether or thioether using an *N*-substituted 3-chloropropylamine, and thus also represent additional compounds that may be useful in the practice of the present invention. In addition to $R_1 = H$ (*i.e.*, SN38), additional alternative R_1 groups are also contemplated to be useful in generating analogs and/or derivatives of the exemplary compound, APE-SN38, that are also expected to be pharmacologically effective in the methods of the present invention. Such variables include, without limitation, substituted and unsubstituted C₁-C₆ alkyl (including methyl, ethyl), benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

This example demonstrated that dipropylpropanamide-based linker has been synthesized that has high MAO-B activity/specificity (FIG. 19A). Previously-published work (Palmer *et al.*; 1998; and Yu *et al.*, 2006) showed the general characteristics of *N*-substituted tetrahydropyridine compounds that had high MAO-A and/or MAO-B catalytic activity and/or specificity. For example, 4-cyclohexyl-1-methyl-1,2,3,6-tetrahydropyridine (FIG. 19B) and 1-methyl-4-(3-methylfuran-yl)-1,2,3,6-tetrahydropyridine (FIG. 19C) are excellent MAO-B substrates that exhibit a high degree of MAO-B specificity.

In FIG. 19A, R₁, R₂ and R₃ each consist either of a 'warhead' and/or other substitution, wherein O= may also be substituted for sulfur (S=), and the amide nitrogen may also be substituted for C-R₄. In FIG. 19B, R₂, R₃ and R₄ each consist either of a 'warhead' moiety and/or other substitution, and R₁ and R₅ are other substituents. In FIG. 19C, R₂, R₃ and R₄ each consist either of a 'warhead' moiety and/or other substitution, and R₁ and R₅ are other substituents. In FIG. 19D, R₁, R₂ and R₃ each consist

either of a 'warhead' and/or other substitution, wherein the furanic -O- may also be substituted for sulfur -S- (thiophene), *N*-R₄ (X-pyrrole) or R₄-C-R₅ (5-R₄-R₅-cyclopenta-1,3-diene). The R₁, R₂, R₃, R₅, and R₆ substituents may include, but are not limited to, one or more of halogen, hydroxy-, oxo, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkoxy, alkylthio, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, and heterocyclealkyl, as well as -NR_aR_b, -NR_aC(=O)R_b, -NR_aC(=O)NR_aNR_b, -NR_aC(=O)OR_b, -NR_aSO₂R_b, -C(=O)R_a, -C(=O)OR_a, -C(=O)NR_aR_b, -OC(=O)NR_aR_b, -OR_a, -SR_a, -SOR_a, -S(=O)₂R_a, -OS(=O)₂R_a, and -S(=O)₂OR_a. In addition, each of these substituents may also be further substituted with one or more of the above substituents, including, without limitation, a substituted alkyl, a substituted aryl, a substituted arylalkyl, a substituted heterocycle, and/or a substituted heterocyclealkyl. R_a and R_b in this context may be the same or different and, independently, hydrogen, alkyl, haloalkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl and/or substituted heterocyclealkyl.

"Warhead" therapeutic moiety. Exemplary therapeutic moieties include, but are not limited to, methylation/acetylation agents that are known for their ability to conjugate both DNA and RNA. Examples include nitrogen and sulfur mustards, sulfan derivatives, and platins. In FIG. 20 illustrative DNA/RNA acylation agents are shown that can also be combined with the linker and *N*-substituted tetrahydropyridine [linker-TP] moieties of the present invention to generate additional chemotherapeutics having the desired properties.

EXAMPLE 8 -- ABILITY OF MP-MUS TO TREAT INTRACRANIAL HUMAN GLIOBLASTOMA

In the previous examples, it was shown that MP-MUS can successfully treat human glioblastoma multiforme xenograft cultures in a nude mouse flank model. The present study demonstrates the efficacy of MP-MUS in a nude mouse intracranial model of human glioblastoma, and to demonstrate that MP-MUS is able to cross the blood/brain barrier.

Brain model developments. Recently, Iwami and co-workers (2012) have developed an innovative methodology for the injection of human glioblastoma cultures into mouse brain *via* the postglenoid foramen. Previous orthotopic xenograft models typically required formal craniotomies requiring skin incision, bone removal and skin suturing, all of which are highly invasive and can result in excessive stress for the animals. Percutaneous injection into the adult mouse brain *via* the postglenoid foramen is a technically simpler, is significantly more time efficient, and importantly, is a less-stressful

procedure for the mice to undergo, all of which translate into fewer procedural complications.

Postglenoid foramen injection. Initial studies demonstrated that it was possible to inject mice with a glioblastoma culture directly into the brain, and without the need for drilling through the skull. Some five minutes after injection and recovery from the anesthetic, the mice were walking around and were phenotypically normal within an hour. Fifty mice were injected *via* the postglenoid foramen with 2.5 μL of glioblastoma in tissue culture medium (1,000,000 cells mL^{-1}). All animals survived the procedure without any complications. The onset of symptoms occurred between about 19 to 20 days after injection, with mice losing some ability to cling to an investigator's finger.

The timeline of an exemplary study is outlined below in Table 2. Human GBM cells, which were grown in the flanks of nude mice for 36 days and then grown in tissue culture media, were used as an inoculum.

Monitoring of tumors and symptoms. Sixty mice are each injected with 2.5 μL of glioblastoma in tissue culture medium, at one million cells mL^{-1} , over six hours on day 1. On day six, mice are weighed and split into four groups: two control groups and two treatment groups. Mice are then given either 200 μL saline or 200 μL of 1 mg/mL MP-MUS in saline, *via* tail-vein injection, on days 7, 14 and 21.

One control/treatment pairing, Groups A and X, are used to measure the shrinkage of $n = 5$ tumors 24 hours after Saline/MP-MUS treatment; days 8, 15 and 22. The five mice from these groups are euthanized using CO_2 , their tumor volumes are measured, and then used to establish tissue cultures. The second control/treatment pairing, Groups B and Y, are used to generate symptomatology and death curves. The mice in these groups are monitored every 1-2 days, and the onset of symptoms caused by an intracranial tumor is indicated by ear punching. The onset of symptoms occurs around day 20, and the mice generally require euthanasia some 10 days after the onset of hemiparesis.

TABLE 2

A STUDY EXAMINING THE EFFECT OF MP-MUS ON AN INTRACRANIAL GBM

MODEL

Day 1	60 nude mice injected with 2.5 μL of glioblastoma (1,000,000 cells mL^{-1})			
	Control Groups		MP-MUS Groups	
Day 6	Group A (15)	Group B (15)	Group X (15)	Group Y (15)
Day 7	200 μL saline in tail		200 μL 1 mg/mL MP-MUS in tail	
Day 8	remove	$n = 5$	remove	$n = 5$

	tumors		tumors	
Day 13	Group A (10)	Group B (15)	Group X (10)	Group Y (15)
Day 14	200 μ L saline in tail		200 μ L 1 mg/mL MP-MUS in tail	
Day 15	remove tumors	$n = 5$	remove tumors	$n = 5$
Day 20	Group A (5)	Group B (15)	Group X (5)	Group Y (15)
Day 21	200 μ L saline in tail		200 μ L 1 mg/mL MP-MUS in tail	
Day 22	remove tumors	$n = 5$	remove tumors	$n = 5$
Day XX	Monitor Group B $n = 15$ until $n = 0$		Monitor Group Y $n = 15$ until $n = 0$	

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein in their entirety by express reference thereto:

Albers, A.E., K.A. Rawls, and C.J. Chang, "Activity-based fluorescent reporters for monoamine oxidases in living cells," *Chem. Comm. (Camb.)*, **44**:4647-4649 (2007).

Baskin, D.S., M.A. Widmayer, and M.A. Sharpe, "Quantification and calibration of images in fluorescence microscopy," *Anal. Biochem.*, **404**:118-126 (2010).

Baskin, D.S., M.A. Widmayer, and M.A. Sharpe, "Quantification of DNase type I ends, DNase type II ends, and modified bases using fluorescently labeled ddUTP, terminal deoxynucleotidyl transferase, and formamidopyrimidine-DNA glycosylase," *Biotechniques*, **49(1)**:505-512 (2010).

Berridge, M.V. *et al.*, "Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction," *Biotechnol. Annu. Rev.*, **11**:127-152 (2005).

Binda, C. *et al.*, "Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs," *J. Med. Chem.*, **50(23)**:5848-5852 (2007).

Boveris, A. and B. Chance, "The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen," *Biochem. J.*, **134(3)**:707-716 (1973).

Castagnoli, K., *et al.*, "The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine," *Chem. Res. Toxicol.*, **10(4)**:364-368 (1997).

Castagnoli, K., S. Palmer, and Castagnoli N, Jr., "Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity," *Neurobiol.*, **7(2)**:135-149 (1999).

5 Decker, T. and M.L. Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," *J. Immunol. Methods*, **115(1)**:61-69 (1988).

De Colibus, L., *et al.*, "Three-dimensional structure of human monoamine oxidase A (MAO-A): Relation to the structures of rat MAO-A and human MAO-B," *Proc. Natl. Acad. Sci. USA*, **102**:12684-12689 (2005).

10 Differding, E. and L. Ghosez, "Intramolecular Diels-alder cyclo-additions of vinylketenimines: a convergent route to carbazoles and pyridocarbazole alkaloids," *Tetrahedron Lett.*, **26(13)**:1647-1650 (1985).

Dröge, W., "Free radicals in the physiological control of cell function," *Physiol. Rev.*, **82(1)**:47-95 (2002).

15 Efange, S.M.N. and R.J. Boudreau, "Molecular determinants in the bioactivation of the dopaminergic neurotoxin *N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)," *J. Comp. Aided Mol. Des.*, **5(5)**:405-417 (1991).

Flamand, V., H. Zhao, and D.M. Peehl. "Targeting monoamine oxidase A in advanced prostate cancer," *J. Cancer Res. Clin. Oncol.*, **136(11)**:1761-1771 (2010).

20 Fukuda, T., "Neurotoxicity of MPTP," *Neuropathology*, **21(4)**:323-332 (2001).

Gabilondo, A.M., *et al.*, "Monoamine oxidase B activity is increased in human Gliomas," *Neurochem. Int.*, **52(1-2)**:230-234 (2008).

Geha, R.M., I. Rebrin, K. Chen, and J.C. Shih, "Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid," *J. Biol. Chem.*, **276(13)**:9877-9882 (2001).

25 Gimenez, B.G., *et al.*, "Evaluation of blockbuster drugs under the rule-of-five. *Pharmazie*, **65(2)**:148-152 (2010).

Hao, R., M. Ebadi, and R.F. Pfeiffer, "Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease," *Neurosci. Lett.*, **200(2)**:77-80 (1995).

30 Hare, M.L.C., "Tyramine oxidase: A new enzyme system in liver," *Biochem. J.*, **22(4)**:968-979 (1928).

Heikkila, R.E., *et al.*, "Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine," *Proc. Natl. Acad. Sci. USA*, **85**:6172-6176 (1988).

5 Huet, O., *et al.*, "NADH-dependent dehydrogenase-activity estimation by flow cytometric analysis of 3-(4,5-dimethylthiazolyl-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) reduction," *Cytometry*, **13(5)**:532-539 (1992).

Iwami, K., *et al.*, "A novel method of intracranial injection via the postglenoid foramen for brain tumor mouse models," *J. Neurosurgery*, **116**:630-635 (2012).

10 Jekabsone, A., *et al.*, "Fibrillar beta-amyloid peptide A β_{1-40} activates microglial proliferation *via* stimulating TNF- α release and H₂O₂ derived from NADPH oxidase: a cell culture study," *J. Neuroinflammation*, **3**:24 (2006).

Jian, Y., "Synthesis and mechanistic studies on the monoamine oxidase (MAO) catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridines," *in Chemistry*, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA, p. 179 (1998).

15 Korzeniewski, C. and D.M. Callewaert, "An enzyme-release assay for natural cytotoxicity," *J. Immunol. Methods*, **64(3)**:313-320 (1983).

Lajiness, M.S., M. Vieth, and J. Erickson, "Molecular properties that influence oral drug-like behavior," *Curr. Opin. Drug Discov. Develop.*, **7(4)**:470-477 (2004).

20 Lipinski, C.A., *et al.*, "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings," *Adv. Drug Delivery Rev.*, **46(1-3)**:3-26 (2001).

Lipinski, C.A., *et al.*, "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings," *Adv. Drug Delivery Rev.*, **23**:3-25 (1997).

25 Malmström, B.G., L.E. Andréasson, and B. Reinhammar, "Copper-containing oxidases and superoxide dismutase. *in*: P.D. Boyer, (Ed.), **The Enzymes**, Academic Press, New York, pp. 507-579 (1975).

Mander, P.K., A. Jekabsone, and G.C. Brown, "Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase," *J. Immunol.*, **176(2)**:1046-1052 (2006).

30 Nimkar, S.K., *et al.*, "Studies on the monoamine oxidase-B-catalyzed biotransformation of 4-azaaryl-1-methyl-1,2,3,6-tetrahydropyridine derivatives," *J. Med. Chem.*, **42(10)**:1828-1835 (1999).

Palmer, S.L. "The investigation of the active sites of monoamine oxidase (MAO) A and B and the study of MAO-A mediated neurotoxicity using 4-substituted

tetrahydropyridines,” Ph.D. thesis, Department of Chemistry, Virginia Polytechnic Institute, Blacksburg, VA, USA (1998).

Palmer, S.L., S. Mabic, and N. Castagnoli Jr., “Probing the active sites of monoamine oxidase A and B with 1,4- di-substituted tetrahydropyridine substrates and
5 inactivators,” *J. Med. Chem.*, **40(13)**:1982-1989 (1997).

Price, C.C., *et al.*, “Relative reactivities for monofunctional nitrogen mustard alkylation of nucleic acid components,” *Biochim. Biophys. Acta*, **166(2)**:327-359 (1968).

Sharpe, M.A., *et al.*, “Thimerosal-derived ethylmercury is a mitochondrial toxin in human astrocytes: possible role of Fenton chemistry in the oxidation and breakage of
10 mtDNA,” *J. Toxicol.*, **2012**:1-12 (2012).

Slimak, D.M., “Molinspiration Cheminformatics,” retrieved from <http://www.molinspiration.com/> (2010).

Toninello, A., *et al.*, “Amine oxidases in apoptosis and cancer,” *Biochim. Biophys. Acta*, **1765**:1-13 (2006).

True, L., *et al.*, “A molecular correlate to the Gleason grading system for prostate adenocarcinoma,” *Proc. Natl. Acad. Sci. USA*, **103(29)**:10991-10996 (2006).

van de Waterbeemd, H., *et al.*, “Estimation of blood-brain barrier crossing of drugs using molecular size and shape and H-bonding descriptors,” *J. Drug Target.*, **6(2)**:151-165 (1998).

Veber, D.F., *et al.*, “Molecular properties that influence the oral bioavailability of drug candidates,” *J. Med. Chem.*, **45(12)**:2615-2623 (2002).

Vizi, E.S., “Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system,” *Pharmacol. Rev.*, **52**:63-90 (2000).

Wang, Y.X. and N.J. Castagnoli, “Studies on the monoamine oxidase (MAO)-catalyzed oxidation of phenyl-substituted 1-methyl-4-phenoxy-1,2,3,6-tetrahydropyridine derivatives: factors contributing to MAO-A and MAO-B selectivity,” *J. Med. Chem.*, **38(11)**:1904-1910 (1995).

Yao, Y.-S., *et al.*, “Total synthesis of 7-ethyl-10-hydroxycamptothecin (SN38) and its application to the development of C₁₈-functionalized camptothecin derivatives,”
30 *Chemistry*, **17(37)**:10462-10469 (2011).

Youngster, S.K., P.K. Sonsalla, and R.E. Heikkila, “Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” *J. Neurochem.*, **48(3)**:929-934 (1987).

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of exemplary
5 embodiments, it will be apparent to those of ordinary skill in the art that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents that are both
10 chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those of ordinary skill in the art are deemed to be within the spirit, scope and concept of the invention as defined herein.

THE CLAIMS:

WHAT IS CLAIMED IS:

- 5 1. A compound for treating cancer, comprising a first targeting/seeker moiety that is specific for a mammalian monoamine oxidase (MAO) enzyme, operably linked to a first therapeutic moiety *via* at least a first linker moiety, wherein the first therapeutic moiety is a neutral, blood-brain barrier-permeable pro-drug.
- 10 2. The compound of claim 1, wherein the first therapeutic moiety is a DNA acylating or DNA damaging agent.
- 15 3. The compound of claim 1 or claim 2, wherein the first targeting/seeker moiety has as specificity for MAO-B enzyme that is at least two-fold greater than the corresponding specificity for MAO-A enzyme.
- 20 4. The compound of any preceding claim, wherein the first targeting/seeker moiety has as specificity for MAO-B enzyme that is at least three-fold greater than the corresponding specificity for that of MAO-A enzyme.
- 25 5. The compound of any preceding claim, wherein the first targeting moiety is converted by the enzymatic action of MAO-A or MAO-B to its corresponding 1-methyl-4-(X)-pyridinium cationic form.
- 30 6. The compound of any preceding claim, wherein the resulting 1-methyl-4-(X)-pyridinium cationic form of the first targeting moiety facilitates uptake of the compound by the mitochondrial membrane of a mammalian cell at a rate that is at least about 5-fold to about 10-fold higher than that of the corresponding, non-ionic form of the compound.
7. The compound of any preceding claim, wherein the resulting 1-methyl-4-(X)-pyridinium cationic form of the first targeting moiety facilitates accumulation of the first therapeutic moiety in the mitochondria of a population of mammalian cells to which the compound has been administered, in an amount that is about 50- to

about 500-fold higher than the concentration of the first therapeutic moiety found in the cytosol of the cells upon administration of the compound to the cells.

8. The compound of any preceding claim, wherein the first targeting/seeker moiety is selected from the group consisting of 1-methyl-1,2,3,6-tetrahydropyridine, 1-cyclopropyl-1,2,3,6-tetrahydropyridin-, and any combination, analog, or derivative thereof.
9. The compound of any preceding claim, wherein the first therapeutic moiety is a nitrogen mustard, a sulfur mustard, a platin tetranitrate, vinblastine, docetaxel, etoposide, SN-38, camptothecin, carmustine, or any combination, analog, derivative, or salt thereof.
10. The compound of any preceding claim, wherein the first therapeutic moiety is operably linked to the linker group, and selected from the group consisting of bis(2-chloroethyl) [Linker-TP]amine, 1-[(2-R₁-2-R₂-2-[Linker-TP]ethyl)sulfanyl]-3-chloropropane, ({[(3-chloropropyl)sulfanyl] methyl})[Linker-TP]- R₁-amine, 3-[Linker-TP]-4-(methanesulfonylmethoxy)butyl methanesulfonate, 1,10-dichloro-5-[Linker-TP]-2,9-diaza-1,10-diplatinadecane-1,1,10,10-tetramine, or 2,2-diamino-5-[Linker-TP]-1,3-dioxa-2-platinacyclohexane-4,6-dione.
11. The compound of any preceding claim, wherein the at least a first linker moiety is selected from the group consisting of 2-methylpropanamide, cyclohexane, and any derivative, analog, or salt thereof.
12. The compound of any preceding claim, defined as 2-R₃-N-R₂-N-R₁-2-(1-X-1,2,3,6-tetrahydropyridin-4-yl) acetamide, 4-phenyl-1-X-1,2,3,6-tetrahydropyridine, 4-cyclohexyl-1-X-1,2,3,6-tetrahydropyridine, or 4-(5-R₁-4-R₂-3-R₃-furan-2-yl)-1-X-1,2,3,6-tetrahydropyridine,

wherein R₁, R₂, R₃, and R₅, are each halogen, hydroxyl, oxo, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkoxy, alkylthio, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, -NR_aR_b, -NR_aC(=O)R_b, -NR_aC(=O)NR_aNR_b, -NR_aC(=O)OR_b, -NR_aSO₂R_b, -C(=O)R_a, C(=O)OR_a,

-C(=O)NR_aR_b, -C(=O)NR_aR_b, -OR_a, -SR_a, -SOR_a, -S(=O)₂R_a, -OS(=O)₂R_a, -S(=O)₂OR_a, substituted alkyl, substituted aryl, substituted arylalkyl, substituted heterocycle, or substituted heterocyclealkyl;

- 5 wherein R_a and R_b are the same or different and, are, independently, hydrogen, alkyl, haloalkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl, and
- 10 further wherein X is a chemotherapeutic moiety selected from the group consisting of a nitrogen mustard, a sulfur mustard, a platin tetranitrate, *cis*-platin, or a derivative or salt thereof.
13. The compound of any preceding claim, defined as P+-MUS or P+-SN38.
- 15
14. The compound of any preceding claim, admixed with one or more pharmaceutically-acceptable carriers, diluents, excipients, or any combination thereof.
- 20 15. The compound of any preceding claim, admixed with one or more other antineoplastic agents, one or more other cytotoxic agents, one or more cytostatic agents, or one or more therapeutic or chemotherapeutic agents, or any combination thereof.
- 25 16. The compound of any preceding claim, admixed with one or more other antineoplastic agents selected from the group consisting of a sulfan, a platin tetranitrate, a nitrogen mustard, a sulfur mustard, a *cis*-platin, a topoisomerase, a radiotherapeutic, a chemotherapeutic, and any derivative, salt, or combination thereof.
- 30
17. The compound of any preceding claim, admixed with one or more other antineoplastic agents that are selected from the group consisting of camptothecin, temozolomide, SN-38, vinblastine, docetaxel, etoposide, carmustine, a nitrogen mustard, a sulfur mustard and any combination thereof.

18. The compound of any preceding claim, formulated for administration to a mammalian host cell.
- 5 19. The compound of any preceding claim, adapted and configured as part of a therapeutic kit that comprises the compound, and at least a first set of instructions for administration of the compound to a human in need thereof.
- 10 20. The compound of any preceding claim, for use in therapy, prophylaxis, or amelioration of one or more symptoms of a mammalian cancer.
21. The compound of any preceding claim, for use in the therapy, prophylaxis, or amelioration of one or more symptoms of a human glioma.
- 15 22. The compound of any preceding claim, for use in the therapy, prophylaxis, or amelioration of one or more symptoms of a tumor that is diagnosed or is identified as, Glioblastoma Multiforme (GBM), a recurrent Glioblastoma Multiforme (rGBM), an astrocytoma, an ependymoma, an oligodendroglioma, a brainstem glioma, a mixed glioma, or any combination thereof.
- 20 23. The compound of any preceding claim, for use in the therapy, prophylaxis, or amelioration of one or more symptoms of a tumor that is diagnosed or identified as an advanced-stage or an advanced-grade GBM.
- 25 24. The compound of any preceding claim, wherein the malignant glioma is a radiation-resistant glioma or comprises one or more glioma stem cells.
25. The compound of any preceding claim, wherein the first therapeutic agent comprises at least a first MAO-active moiety.
- 30 26. Use of a compound in accordance with any one of claims 1 to 25, in the manufacture of a medicament for treating or ameliorating at least one symptom of a cancer in a mammalian subject.

27. Use in accordance with claim 26, wherein the mammalian subject is a human, a non-human primate, a companion animal, an exotic, or a livestock.
28. A pharmaceutical composition for use in the therapy of cancer in an animal subject,
5 comprising at least a first compound in accordance with any one of claims 1 to 25.
29. A MAO-B-convertible tetrahydropyridine chemotherapeutic delivery compound operably linked, *via* a first chemical linker moiety, to at least a first chemotherapeutic agent that has DNA acylating or DNA damaging activity in the
10 mitochondria of a mammalian gliomal cancer cell.
30. The MAO-B-convertible tetrahydropyridine chemotherapeutic delivery compound of claim 29, operably linked to at least a first nitrogen mustard, a sulfur mustard, a sulfan, *cis*-platin, a platin tetranitrate, temozolomide, camptothecin, irinotecan,
15 carmustine, or any derivative, active metabolite, or analog thereof.
31. The MAO-B-convertible tetrahydropyridine chemotherapeutic delivery compound of claim 29 or claim 30, wherein the active metabolite is the SN38 metabolite of the pro-drug camptothecin.
20
32. The MAO-B convertible tetrahydropyridine chemotherapeutic delivery compound of any one of claims 29 to 31, having the general formula 1-methyl-4-(X)-pyridine, wherein X is as defined in FIG. 23.
- 25 33. The MAO-B convertible tetrahydropyridine chemotherapeutic delivery compound of any one of claims 29 to 32, defined as MP-MUS.
34. A method of preventing, treating or ameliorating at least one or more symptoms of cancer in an animal in need thereof, the method comprising administering to the
30 animal an effective amount of: a) a compound in accordance with any one of claims 1 to 25; b) the composition of claim 28, or c) the MAO-B convertible tetrahydropyridine chemotherapeutic delivery compound of any one of claims 29 to 33; for a time sufficient to prevent, treat or ameliorate the at least one or more symptoms of the cancer in the animal.

35. A method for inhibiting the growth of a mammalian cancer cell or tumor, the method comprising providing to the cell or to the tumor, an effective amount of: a) a compound in accordance with any one of claims 1 to 25; b) the composition of claim 28, or c) the MAO-B convertible tetrahydropyridine chemotherapeutic delivery compound of any one of claims 29 to 33; for a time effective to inhibit the growth of the cancer cell or the tumor.

36. A method for treating or ameliorating at least one symptom of a cancer in a mammalian subject, the method comprising administering to a mammalian subject in need thereof: (a) a therapeutically-effective amount of a compound in accordance with any one of claims 1 to 25, the composition of claim 28, or the MAO-B-convertible tetrahydropyridine chemotherapeutic delivery compound of any one of claims 29 to 33, and (b) a therapeutically-effective amount of at least a first ionizing radiation, each in an amount and for a time sufficient to treat or ameliorate the at least one symptom of the cancer in the mammalian subject.

37. A method of increasing the effectiveness of a chemotherapeutic agent in killing cancer cells in an animal, comprising chemically linking the agent to a MAO-convertible mitochondria-seeking drug delivery moiety to form a mitochondrial-targeting composition, and then providing an effective amount of the resulting chemotherapeutic composition to one or more cells, tissues, or organs of the animal, wherein the effectiveness of the composition for killing one or more cancer cells in the animal is greater than the effectiveness of the un-linked agent alone.

38. A method of targeting a chemotherapeutic agent to one or more cancer cell mitochondria in an animal in need of anti-cancer therapy, comprising chemically linking the chemotherapeutic agent to an inactive pro-drug that is convertible to its active form by the enzymatic action of a mitochondrial MAO, and then providing an effective amount of the composition to one or more cells, tissues, or organs of the animal, wherein the level of chemotherapeutic agent localized to the mitochondria is substantially higher than the level of chemotherapeutic agent remaining in the cytosol of the one or more cancer cells.

39. The method in accordance with any one of claims 36 to 38, wherein the chemotherapeutic composition comprises the mitochondrially-localizable active cytotoxic compounds P⁺-MUS, P⁺-SN38, or any combination, derivative, or active metabolite thereof.

5

40. The method in accordance with any one of claims 36 to 39, wherein the chemotherapeutic composition further comprises a second chemotherapeutic agent selected from the group consisting of temozolomide, carmustine, a nitrogen mustard, a sulfur mustard, a sulfan, *cis*-platin, a platin tetranitrate, camptothecin, irinotecan, lomustine, or any derivative, active metabolite, or analog thereof.

10

1/31




4-(1-[bis(2-chloroethyl) carbamoyl]ethyl)-1-(X)-1-ium	1-(2-chloroethyl)-1-2-(X)-propanoyl)aziridin-1-ium
	
	
3-(2-chloroethyl)-2-(1-(X)-ethyl)-4,5-dihydro-1,3-oxazol-3-ium	

FIG. 1B






MAO-B	
	
N,N-bis(2-chloroethyl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)propanamide	4-(1-[bis(2-chloroethyl) carbamoyl]ethyl)-1-methylpyridin-1-ium

FIG. 1A

2/31**FIG. 2A****FIG. 2B**

3/31



Resorufin and propanal

FIG. 3

4/31




FIG. 4

5/31










FIG. 5

6/31**FIG. 6A****FIG. 6B**

7/31**FIG. 7A****FIG. 7B****FIG. 7C****FIG. 7D**

8/31




FIG. 8A




FIG. 8B




FIG. 8C

9/31




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E










FIG. 9F

10/31**FIG. 10A****FIG. 10B**

11/31**FIG. 11A****FIG. 11B**

12/31**FIG. 12**

13/31**FIG. 13A**

14/31

Lipophilic cations and mitochondria




FIG. 13B

15/31




FIG. 14

16/31




FIG. 15

17/31




FIG. 16

18/31

Moiety	Function	Examples
Chemotherapeutic moiety (i.e., "warhead")	Damages macromolecules Connects warhead to seeker and provides MAOA/B specificity	Nitrogen mustard, Platin tetranitrate
Linker		2-methylpropanamide, cyclohexane
Targeting moiety (i.e., "Seeker")	Undergoes conversion into pyridinium cation and mature species accumulates in mitochondria	1-methyl-1,2,3,6- tetrahydropyridine, 1-cyclopropyl-1,2,3,6- tetrahydropyridin-







FIG. 17

19/31**FIG. 18**


20/31




2-R3-N-R2-N-R1-2-(1-X-1,2,3,6-tetrahydropyridin-4-yl) acetamide

FIG. 19A



4-phenyl-1-X-1,2,3,6-tetrahydropyridine

FIG. 19B


4-cyclohexyl-1-X-1,2,3,6-tetrahydropyridine

FIG. 19C


4-(5-R1-4-R2-3-R3-furan-2-yl)-1-X-1,2,3,6-tetrahydropyridine

FIG. 19D**FIG. 19E****FIG. 19F**


21/31

Sulfur Mustard:


({[(3-chloropropyl)sulfanyl]
methyl]})[Linker-TP]-R1-
amine

FIG. 19G**Sulfan:**

3-[Linker-TP]-4-
(methanesulfonylmethoxy)butyl
methanesulfonate

FIG. 19H**Platin tetranitrate:**

1, 10-dichloro-5-[Linker-TP]-2,9-
diazia-1, 10-di-platinadecane-
1,1,10,10-tetramine

FIG. 19I**cis-Platin derived:**

2,2-diamino-5-[Linker-TP]-1,3-dioxa-
2-platinacyclohexane-4,6-dione

FIG. 19J

22/31










Structure	Name
	(3-chloropropyl)(ethynyl)amine; N-(3-
	chloropropyl)cyclobutanamine; N-(3-
	chloropropyl)cyclopropanamine; [(3-
	chloropropyl)amino]methanol;
	tert-butyl(3-chloropropyl)amine
	[R1, R2, R3, methyl](3-chloropropyl)amine;
Substituents R1, R2 and R3 include, but are not limited to, halogen, hydroxy, oxo, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkoxy, alkylthio, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, and heterocyclealkyl, as well as, -NR _a R _b , -NR _a C(=O)R _b , -NR _a C(=O)NR _a NR _b , -NR _a C(=O)OR _b , -NR _a SO ₂ R _b , -C(=O)R _a , -C(=O)OR _a , -C(=O)NR _a R _b , -OC(=O)NR _a R _b , -OR _a , -SR _a , -SOR _a , -S(=O) ₂ R _a , -OS(=O) ₂ R _a and -S(=O) ₂ OR _a .	


FIG. 20

23/31**FIG. 21A****FIG. 21B**


24/31




Vinblastine (vinca alkaloid)

FIG. 22A

Docetaxel (taxel)

FIG. 22B

SN-38 (Topoisomerase I)





FIG. 22C

Etoposide (Topoisomerase II)



FIG. 22D

25/31

MAO-A and B Activity of Various MPTP Derivatives.				
Substrates	Substitution	MAO-A Kcat	MAO-B Kcat	B/A
MPTP	3x H	143	523	3.66
R1	-CH ₃	593	1,275	2.15
R1	-CH ₂ CH ₃	688	295	0.4
R1	-n-propyl	658	86	0.131
R1	-OCH ₃	511	233	0.456
R1	-CF ₃	520	0.33	0.000635
R1	-F	100	1,054	10.54
R1	-Cl	400	1,353	3.383
R1	-isopropyl	1,131	51	0.0451
R2	-CH ₃	76	650	8.553
R2	-F	391	900	2.302
R2	-Cl	567	1,132	1.9965
R2	-Br	300	2,036	6.79
R2	-OCH ₃	0	944	>1000
R2	-CF ₃	214	514	2.4
R3	-CH ₃	58	345	5.95
R3	-F	0	423	>1000
R3	-Cl	69	595	8.63
R3	-NH ₂	12	54	4.5
R3	-NO ₂	185	16	0.087
Data from Palmer et al., 1997 and Palmer 1998. Showing the effects of substitution on MPTP on the kinetics of MAO-A/B.				

FIG. 23A**MPTP****FIG. 23B****MAO-B****FIG. 23C****Ideal MAO-A substrate****FIG. 23D****Ideal MAO-B substrate****FIG. 23E**

26/31

In vivo Studies:**Q1: MP-MUS rapidly shrinks GBM tumors**Single 8 μ g/g MP-MUS tail-vein injection at 24 hours**FIG. 24A****FIG. 24B**

27/31

GBM cells growing out of tumor




FIG. 25

28/31

GBM from Saline treated




FIG. 26A

GBM from MP-MUS treated




FIG. 26B

29/31




FIG. 27

30/31




FIG. 28




FIG. 29

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2012/062850

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K31/435 A61K31/4375 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, BIOSIS, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 94/29333 A1 (BURROUGHS WELLCOME CO [US]; BLACK CHRISTOPHER D V [US]; SNOW ROBERT AL) 22 December 1994 (1994-12-22) claims 2,14	1-8,11, 14-28, 34-38 9,10,13, 16,17, 29-33, 39,40
X	----- WO 2011/035332 A1 (CHEMOCENTRYX INC [US]; CHARVAT TREVOR T [US]; CHU HIUFUNG [US]; KRASIN) 24 March 2011 (2011-03-24) paragraph [0062] figure 3/32 ----- <div style="text-align: center;">- / - -</div>	1-8,11, 14-28, 34-38
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex. </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
22 January 2013	10/05/2013	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Büttner, Ulf	

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2012/062850

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2011/110889 A1 (AHRENDT ET AL KATERI A [US] ET AL) 12 May 2011 (2011-05-12) paragraphs [0303], [0593], [0711] paragraph [0424] paragraph [0413] -----	1-8, 14-29, 34-38,40
X	US 2009/197864 A1 (LI AN-HU [US] ET AL) 6 August 2009 (2009-08-06) page 7 paragraph [1375] - paragraph [1380] -----	1-8, 14-29, 34-38,40
Y	WO 98/22110 A1 (VIRGINIA TECH INTELL PROP [US]; CASTAGNOLI NEAL JR [US]; FLAHERTY PATR) 28 May 1998 (1998-05-28) claims 1-13 page 4, line 7 -----	1-11, 13-40
A	US 4 913 891 A (FOWLER JOANNA S [US] ET AL) 3 April 1990 (1990-04-03) claims -----	1-11, 13-40
Y	GABILONDO ET AL: "Monoamine oxidase B activity is increased in human gliomas", NEUROCHEMISTRY INTERNATIONAL, PERGAMON PRESS, OXFORD, GB, vol. 52, no. 1-2, 12 December 2007 (2007-12-12), pages 230-234, XP022386354, ISSN: 0197-0186, DOI: 10.1016/J.NEUINT.2007.05.015 cited in the application page 233 -----	1-11, 13-40
A	NAKAO A ET AL: "Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: Part 3", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 20, no. 16, 15 August 2010 (2010-08-15), pages 4774-4778, XP027172620, ISSN: 0960-894X [retrieved on 2010-07-01] table 1 -----	1-11, 13-25, 28-33

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2012/062850

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

5-8, 10, 29-31, 33(completely); 1-4, 9, 11, 13-28, 32, 34-40(partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 5-8, 10, 29-31, 33(completely); 1-4, 9, 11, 13-28, 32, 34-40(partially)

A compound for treating cancer comprising a first targeting/seeker moiety that is specific for a mammalian monoamine oxidase (MAO) enzyme, operably linked to a first therapeutic moiety via at least a first linker moiety, wherein the first therapeutic moiety is a neutral, blood-brain barrier-permeable pro-drug wherein the first targeting moiety is selected from the group consisting of 1-methyl-1,2,3,6-tetrahydropyridine, 1-cyclopropyl-1,2,3,6-tetrahydropyridine-, and any combination, analog, or derivative thereof.

2. claims: 1-4, 9, 11, 13-28, 34-40(all partially)

A compound for treating cancer comprising a first targeting/seeker moiety that is specific for a mammalian monoamine oxidase (MAO) enzyme, operably linked to a first therapeutic moiety via at least a first linker moiety, wherein the first therapeutic moiety is a neutral, blood-brain barrier-permeable pro-drug wherein one moiety is selected from the moieties as shown in Fig. 20 of the application.

3. claims: 1-4, 9, 11, 13-28, 34-38, 40(all partially)

A compound for treating cancer comprising a first targeting/seeker moiety that is specific for a mammalian monoamine oxidase (MAO) enzyme, operably linked to a first therapeutic moiety via at least a first linker moiety, wherein the first therapeutic moiety is a nitrogen mustard, a sulfur mustard, a platinum tetranitrate, vinblastine, docetaxel, etoposide, SN-38, camptothecin, carmustine, or any combination, analog, derivative, or salt thereof.

4. claims: 12(completely); 14-28, 34-38, 40(partially)

A compound for treating cancer comprising a first targeting/seeker moiety that is specific for a mammalian monoamine oxidase (MAO) enzyme, operably linked to a first therapeutic moiety via at least a first linker moiety, wherein the compound is defined as 2-R3 -N-R2 -N-R1 -2-(1-X-1,2,3,6-tetrahydropyridin-4-yl) acetamide, 4-phenyl-1-X-1,2,3,6-tetrahydropyridine, 4-cyclohexyl-1-X-1,2,3,6-tetrahydropyridine, or 4-(5-R1 -4-R2 -3-R3 -furan-2-yl)-1-X-1,2,3,6-tetrahydropyridine, wherein R1 , R2

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

, R3 , and Rs , are each halogen, hydroxyl, oxo, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkoxy, alkylthio, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, -NR, Rb , -NRa C(=O)Rb , -NR.C(=O)NRaNRb , -NRa C(=O)ORb -NRa SO2Rb , -C(=O)Ra , C(=O)ORa, -C(=O)NRa Rb , -C(=O)NRaRb, -ORa, -SRa, -SORa, -S(=O)2R., -OS(=O)2R., -S(=O)2ORa , substituted alkyl, substituted aryl, substituted arylalkyl, substituted heterocycle, or substituted heterocyclealkyl; wherein Ra and Rb are the same or different and, are, independently, hydrogen, alkyl, haloalkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocycloalkyl, and further wherein X is a chemotherapeutic moiety selected from the group consisting of a nitrogen mustard, a sulfur mustard, a platinum tetranitrate, cis-platin, or a derivative or salt thereof.

5. claims: 32, 34-38(all partially)

Compounds 23B, 23D, 23E of claim 32 (insofar compound as claim 32 should relate to these compounds).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2012/062850

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9429333	A1	22-12-1994	AU	7244894 A	03-01-1995
			CA	2164518 A1	22-12-1994
			EP	0710244 A1	08-05-1996
			JP	H09501147 A	04-02-1997
			WO	9429333 A1	22-12-1994

WO 2011035332	A1	24-03-2011	CN	102574789 A	11-07-2012
			EP	2480531 A1	01-08-2012
			US	2011082172 A1	07-04-2011
			WO	2011035332 A1	24-03-2011

US 2011110889	A1	12-05-2011	AR	070535 A1	14-04-2010
			AU	2009222143 A1	11-09-2009
			CA	2716951 A1	11-09-2009
			CN	102015707 A	13-04-2011
			EC	SP10010510 A	30-10-2010
			EP	2265608 A2	29-12-2010
			JP	2011513330 A	28-04-2011
			KR	20100122505 A	22-11-2010
			PE	15612009 A1	30-10-2009
			TW	200940540 A	01-10-2009
			US	2011110889 A1	12-05-2011
			WO	2009111278 A2	11-09-2009

US 2009197864	A1	06-08-2009	AR	070317 A1	31-03-2010
			AU	2009212338 A1	13-08-2009
			CA	2711078 A1	13-08-2009
			CN	102007127 A	06-04-2011
			EA	201070929 A1	29-04-2011
			EP	2265616 A1	29-12-2010
			JP	2011511094 A	07-04-2011
			KR	20110014971 A	14-02-2011
			PE	14142009 A1	23-09-2009
			TW	200944201 A	01-11-2009
			US	2009197864 A1	06-08-2009
			UY	31638 A1	30-09-2009
			WO	2009100282 A1	13-08-2009

WO 9822110	A1	28-05-1998	NONE		

US 4913891	A	03-04-1990	NONE		
